No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 2f3fA, 1.0000, 0.00, 1.000, 375, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
2, 3qbhA, 0.9984, 0.27, 1.000, 375, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
3, 2f3fB, 0.9982, 0.31, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
4, 2f3eA, 0.9980, 0.34, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
5, 4d8cA, 0.9975, 0.36, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
6, 4d83A, 0.9975, 0.37, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
7, 3pi5A, 0.9975, 0.38, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
8, 3k5dA, 0.9974, 0.36, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
9, 2f3eB, 0.9973, 0.39, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
10, 3k5dC, 0.9972, 0.38, 1.000, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
11, 4trwA, 0.9969, 0.40, 1.000, 389, 375, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
12, 1ym2A, 0.9968, 0.42, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
13, 4lxkA, 0.9967, 0.45, 0.997, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
14, 4lxmA, 0.9965, 0.44, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
15, 3pi5B, 0.9965, 0.44, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
16, 4d83B, 0.9963, 0.45, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
17, 4lxaA, 0.9962, 0.48, 0.997, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
18, 4lxkB, 0.9961, 0.46, 1.000, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
19, 3k5gA, 0.9961, 0.46, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH BJC060
20, 3k5cA, 0.9961, 0.46, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH NB-216
21, 4lxaB, 0.9960, 0.46, 1.000, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
22, 4d8cB, 0.9960, 0.47, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
23, 3k5cB, 0.9957, 0.49, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH NB-216
24, 3qbhB, 0.9956, 0.51, 0.997, 376, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
25, 3k5gB, 0.9956, 0.49, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH BJC060
26, 3k5fB, 0.9956, 0.50, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH AYH011
27, 3dv5A, 0.9955, 0.50, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
28, 3dv1A, 0.9954, 0.51, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
29, 4lxmB, 0.9952, 0.52, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
30, 4trwC, 0.9951, 0.50, 0.995, 390, 375, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
31, 2f3fC, 0.9951, 0.55, 1.000, 377, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
32, 4tryA, 0.9945, 0.37, 1.000, 387, 374, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
33, 3cidB, 0.9942, 0.58, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH726222
34, 3cicB, 0.9942, 0.58, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH709583
35, 3qbhC, 0.9941, 0.59, 1.000, 375, 375, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
36, 3lpjB, 0.9941, 0.59, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH743641
37, 6dhcA, 0.9940, 0.60, 1.000, 378, 375, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
38, 3cibB, 0.9940, 0.59, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH727596
39, 1xn2A, 0.9940, 0.58, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
40, 6bfxB, 0.9939, 0.59, 1.000, 388, 375, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
41, 6bfeB, 0.9939, 0.60, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
42, 3dv1B, 0.9939, 0.59, 1.000, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
43, 2qp8B, 0.9939, 0.59, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH734723
44, 2qmgB, 0.9939, 0.60, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH745966
45, 2qmfB, 0.9939, 0.59, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH735310
46, 1fknB, 0.9939, 0.58, 1.000, 389, 375, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
47, 6bfdB, 0.9938, 0.60, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
48, 4trzA, 0.9937, 0.42, 1.000, 388, 374, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
49, 3l58B, 0.9937, 0.61, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH589432
50, 2qmdB, 0.9937, 0.60, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH722924
51, 2qk5B, 0.9937, 0.60, 1.000, 389, 375, STRUCTURE OF BACE1 BOUND TO SCH626485
52, 1m4hB, 0.9937, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
53, 6bfdA, 0.9936, 0.60, 1.000, 393, 375, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
54, 3lpkB, 0.9936, 0.60, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH747123
55, 1xn3C, 0.9936, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
56, 3lpiB, 0.9935, 0.61, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH745132
57, 2qmfA, 0.9935, 0.60, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH735310
58, 2g94B, 0.9935, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
59, 2g94A, 0.9935, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
60, 2f3eC, 0.9935, 0.63, 1.000, 381, 375, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
61, 3lpjA, 0.9934, 0.61, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH743641
62, 3l58A, 0.9934, 0.61, 1.000, 395, 375, STRUCTURE OF BACE BOUND TO SCH589432
63, 3k5dB, 0.9934, 0.62, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
64, 3cibA, 0.9934, 0.61, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH727596
65, 2qmgA, 0.9934, 0.60, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH745966
66, 2g94D, 0.9934, 0.61, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
67, 1xn3D, 0.9934, 0.60, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
68, 1xn2B, 0.9934, 0.61, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
69, 6bfeA, 0.9933, 0.61, 1.000, 393, 375, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
70, 3cicA, 0.9933, 0.61, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH709583
71, 2zhrA, 0.9933, 0.61, 1.000, 390, 375, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
72, 2qmdA, 0.9933, 0.61, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH722924
73, 1ym2B, 0.9933, 0.65, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
74, 2g94C, 0.9932, 0.61, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
75, 1m4hA, 0.9932, 0.62, 1.000, 391, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
76, 3cidA, 0.9931, 0.62, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH726222
77, 2qk5A, 0.9931, 0.62, 1.000, 395, 375, STRUCTURE OF BACE1 BOUND TO SCH626485
78, 1xn2D, 0.9931, 0.62, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
79, 1xn2C, 0.9931, 0.62, 1.000, 389, 375, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
80, 4trwB, 0.9930, 0.63, 1.000, 389, 375, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
81, 2qp8A, 0.9930, 0.62, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH734723
82, 1ym2C, 0.9930, 0.64, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
83, 6bfxA, 0.9929, 0.62, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
84, 6bfwA, 0.9929, 0.63, 1.000, 393, 375, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
85, 5mbwA, 0.9929, 0.63, 1.000, 390, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH PEP#3
86, 3lpkA, 0.9929, 0.63, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH747123
87, 3lpiA, 0.9929, 0.62, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH745132
88, 2vkmC, 0.9929, 0.63, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
89, 1fknA, 0.9929, 0.64, 1.000, 391, 375, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
90, 3pi5C, 0.9928, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
91, 3dv5B, 0.9928, 0.66, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
92, 4lxkC, 0.9927, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
93, 4d8cC, 0.9927, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
94, 4d83C, 0.9927, 0.66, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
95, 4zspB, 0.9926, 0.65, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
96, 3dv5C, 0.9926, 0.66, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
97, 4ybiB, 0.9922, 0.68, 1.000, 388, 375, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
98, 6bfwB, 0.9921, 0.52, 1.000, 387, 374, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
99, 3kn0B, 0.9921, 0.68, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH708236
100, 4zsqA, 0.9920, 0.68, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
101, 4lxaC, 0.9920, 0.69, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
102, 3ohhB, 0.9920, 0.53, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-681889 AKA N~1~-BUTYL-5-CYANO- N~3~-((1S2R)-1-(35- DIFLUOROBENZYL)-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~- METHYL-1H-INDOLE-13- DICARBOXAMIDE
103, 3kmxB, 0.9920, 0.68, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH346572
104, 2vkmD, 0.9920, 0.67, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
105, 3l5fB, 0.9919, 0.68, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH736201
106, 3qi1A, 0.9917, 0.68, 0.995, 382, 375, DESIGN AND SYNTHESIS OF HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS: PRIME SIDE CHROMANE-CONTAINING INHIBITORS
107, 4h3fB, 0.9916, 0.70, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
108, 3k5gC, 0.9916, 0.70, 1.000, 381, 375, HUMAN BACE-1 COMPLEX WITH BJC060
109, 4trzC, 0.9915, 0.54, 1.000, 388, 374, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
110, 1xs7D, 0.9915, 0.70, 1.000, 389, 375, CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).
111, 6dhcB, 0.9914, 0.71, 1.000, 380, 375, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
112, 4tryC, 0.9914, 0.55, 1.000, 388, 374, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
113, 4djxB, 0.9914, 0.71, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
114, 3dv1C, 0.9914, 0.71, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
115, 3ohhA, 0.9913, 0.56, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-681889 AKA N~1~-BUTYL-5-CYANO- N~3~-((1S2R)-1-(35- DIFLUOROBENZYL)-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~- METHYL-1H-INDOLE-13- DICARBOXAMIDE
116, 2p4jC, 0.9913, 0.73, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
117, 4zsqB, 0.9912, 0.71, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
118, 4h3jB, 0.9912, 0.72, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
119, 4fslB, 0.9912, 0.57, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
120, 3kmyB, 0.9912, 0.72, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH12472
121, 3k5fC, 0.9912, 0.72, 1.000, 377, 375, HUMAN BACE-1 COMPLEX WITH AYH011
122, 4zspA, 0.9911, 0.71, 1.000, 390, 375, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
123, 4lxmC, 0.9911, 0.73, 1.000, 381, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
124, 4fslE, 0.9911, 0.58, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
125, 4fslD, 0.9911, 0.58, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
126, 4fslA, 0.9911, 0.58, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
127, 3kmxA, 0.9911, 0.71, 1.000, 395, 375, STRUCTURE OF BACE BOUND TO SCH346572
128, 2p4jA, 0.9911, 0.73, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
129, 5hu0B, 0.9910, 0.73, 1.000, 389, 375, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
130, 4zsmA, 0.9910, 0.71, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
131, 4fseE, 0.9910, 0.58, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
132, 4fseD, 0.9910, 0.59, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
133, 4djyB, 0.9910, 0.73, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
134, 4fseB, 0.9909, 0.59, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
135, 4fseA, 0.9909, 0.59, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
136, 2p4jB, 0.9909, 0.73, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
137, 2vkmA, 0.9907, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
138, 6dhcC, 0.9906, 0.77, 0.997, 377, 375, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
139, 4h3iB, 0.9906, 0.73, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
140, 3kmyA, 0.9906, 0.73, 1.000, 395, 375, STRUCTURE OF BACE BOUND TO SCH12472
141, 1xn3B, 0.9906, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
142, 4zsrA, 0.9905, 0.75, 1.000, 390, 375, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
143, 4h3gB, 0.9905, 0.74, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
144, 4fs4A, 0.9905, 0.73, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
145, 3l5fA, 0.9905, 0.72, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH736201
146, 1xn3A, 0.9905, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
147, 4tryB, 0.9903, 0.64, 1.000, 388, 374, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
148, 4gidC, 0.9903, 0.75, 1.000, 388, 375, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
149, 3k5cC, 0.9903, 0.76, 1.000, 381, 375, HUMAN BACE-1 COMPLEX WITH NB-216
150, 2vkmB, 0.9903, 0.77, 1.000, 389, 375, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
151, 1sgzC, 0.9903, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
152, 1sgzB, 0.9903, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
153, 1sgzA, 0.9903, 0.75, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
154, 4djxA, 0.9902, 0.74, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
155, 4djuB, 0.9902, 0.77, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
156, 3skfA, 0.9902, 0.63, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
157, 4zsrB, 0.9901, 0.80, 1.000, 389, 375, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
158, 4h3fA, 0.9901, 0.74, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
159, 3skfB, 0.9901, 0.63, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
160, 1sgzD, 0.9901, 0.76, 1.000, 389, 375, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
161, 5hu0A, 0.9900, 0.76, 1.000, 390, 375, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
162, 3l5eA, 0.9899, 0.75, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH736062
163, 3l59B, 0.9899, 0.80, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH710413
164, 4zsmB, 0.9898, 0.64, 1.000, 387, 374, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
165, 4djuA, 0.9898, 0.76, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
166, 3l5dB, 0.9898, 0.81, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO SCH723873
167, 3l59A, 0.9898, 0.76, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO SCH710413
168, 3ohfA, 0.9897, 0.66, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-655295 AKA N~3~-((1S2R)-1- BENZYL-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~ N~1~-DIBUTYL-1H-INDOLE-13- DICARBOXAMIDE
169, 4djwA, 0.9896, 0.77, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
170, 4djyA, 0.9895, 0.76, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
171, 3ohfB, 0.9895, 0.66, 1.000, 387, 374, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-655295 AKA N~3~-((1S2R)-1- BENZYL-2-HYDROXY-3-((3- METHOXYBENZYL)AMINO)PROPYL)-N~1~ N~1~-DIBUTYL-1H-INDOLE-13- DICARBOXAMIDE
172, 2p4jD, 0.9895, 0.80, 1.000, 389, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
173, 5htzB, 0.9893, 0.68, 1.000, 389, 374, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
174, 4h3jA, 0.9893, 0.79, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
175, 4djvA, 0.9893, 0.80, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
176, 4djwB, 0.9890, 0.87, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
177, 4djvB, 0.9890, 0.87, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
178, 4h3gA, 0.9888, 0.78, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
179, 4trzB, 0.9887, 0.69, 1.000, 388, 374, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
180, 4ha5A, 0.9886, 0.79, 1.000, 390, 375, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
181, 4fs4B, 0.9886, 0.90, 1.000, 389, 375, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
182, 4gidB, 0.9884, 0.71, 1.000, 387, 374, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
183, 3r2fE, 0.9884, 0.58, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
184, 3r2fD, 0.9884, 0.58, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
185, 3n4lA, 0.9884, 0.61, 0.997, 375, 373, BACE-1 IN COMPLEX WITH ELN380842
186, 3r2fB, 0.9883, 0.58, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
187, 3r2fA, 0.9883, 0.58, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
188, 4ybiA, 0.9882, 0.73, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
189, 4gidD, 0.9882, 0.71, 1.000, 387, 374, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
190, 2fdpC, 0.9882, 0.46, 1.000, 374, 372, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
191, 1ym4A, 0.9881, 0.83, 1.000, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
192, 4x7iB, 0.9877, 0.76, 1.000, 388, 374, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
193, 2zhrB, 0.9877, 0.47, 1.000, 385, 372, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
194, 3skgB, 0.9876, 0.61, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
195, 3skgA, 0.9875, 0.62, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
196, 5mcqA, 0.9874, 0.89, 1.000, 393, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE AND EXOSITE BINDING PEPTIDE INHIBITOR
197, 3skgE, 0.9874, 0.62, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
198, 3hvgA, 0.9871, 0.87, 1.000, 379, 375, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
199, 3skgD, 0.9870, 0.64, 1.000, 386, 373, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
200, 3l5cB, 0.9868, 0.68, 1.000, 387, 373, STRUCTURE OF BACE BOUND TO SCH723871
201, 4x7iA, 0.9867, 0.79, 1.000, 389, 374, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
202, 2oahA, 0.9864, 0.87, 0.995, 378, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
203, 4gidA, 0.9862, 0.82, 1.000, 387, 374, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
204, 4i0fA, 0.9861, 0.91, 0.997, 393, 375, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
205, 3lnkB, 0.9858, 0.59, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH743813
206, 3vf3A, 0.9855, 0.98, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BQQ711
207, 3uqrA, 0.9854, 0.73, 0.997, 377, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
208, 4d88A, 0.9853, 0.99, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXQ490
209, 5mxdC, 0.9851, 0.96, 1.000, 380, 375, BACE-1 IN COMPLEX WITH LIGAND 32397778
210, 4gmiA, 0.9850, 1.00, 1.000, 380, 375, BACE-1 IN COMPLEX WITH HEA-TYPE MACROCYCLIC INHIBITOR MV078571
211, 3ixjA, 0.9850, 0.50, 1.000, 373, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
212, 4r91B, 0.9849, 0.64, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
213, 3udkA, 0.9849, 0.86, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 6
214, 3ixkA, 0.9849, 0.51, 1.000, 373, 371, POTENT BETA-SECRETASE 1 INHIBITOR
215, 3i25A, 0.9849, 0.51, 1.000, 373, 371, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
216, 2ntrA, 0.9849, 0.99, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR
217, 3lnkA, 0.9848, 0.63, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH743813
218, 4r93B, 0.9847, 0.65, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
219, 3veuA, 0.9847, 1.04, 1.000, 380, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-AVI326
220, 3n4lB, 0.9847, 0.65, 0.995, 375, 372, BACE-1 IN COMPLEX WITH ELN380842
221, 1ym4C, 0.9847, 0.94, 1.000, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
222, 4hztA, 0.9846, 0.96, 0.997, 393, 375, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
223, 4r95B, 0.9845, 0.66, 1.000, 386, 372, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
224, 4ha5B, 0.9845, 0.66, 1.000, 386, 372, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
225, 3udhA, 0.9845, 0.87, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 1
226, 5he7B, 0.9844, 0.67, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
227, 5hduB, 0.9844, 0.66, 1.000, 387, 372, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
228, 3l5bB, 0.9844, 0.67, 1.000, 386, 372, STRUCTURE OF BACE BOUND TO SCH713601
229, 5hu1B, 0.9843, 0.67, 1.000, 386, 372, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
230, 4frsB, 0.9843, 0.67, 1.000, 387, 372, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
231, 3u6aB, 0.9842, 0.98, 1.000, 386, 375, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
232, 3l5eB, 0.9842, 0.67, 1.000, 386, 372, STRUCTURE OF BACE BOUND TO SCH736062
233, 5he5B, 0.9841, 0.67, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
234, 3udrA, 0.9841, 0.88, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14
235, 3udmA, 0.9841, 0.88, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 8
236, 3kn0A, 0.9841, 0.66, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH708236
237, 5he4B, 0.9840, 0.68, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
238, 4r8yB, 0.9840, 0.69, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
239, 3udpA, 0.9840, 0.88, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12
240, 5hdvB, 0.9839, 0.69, 1.000, 387, 372, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
241, 4r92B, 0.9839, 0.68, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
242, 4lc7A, 0.9839, 0.99, 1.000, 402, 375, AMINOOXAZOLINE INHIBITOR OF BACE-1
243, 3udyA, 0.9839, 0.89, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 11
244, 5hdxB, 0.9838, 0.69, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
245, 4r91A, 0.9838, 0.68, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
246, 3udjA, 0.9838, 0.90, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 5
247, 4r95A, 0.9837, 0.69, 1.000, 387, 372, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
248, 4d89A, 0.9837, 1.08, 1.000, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A SOAKING EXPERIMENT
249, 3tplB, 0.9837, 0.79, 0.989, 377, 373, APO STRUCTURE OF BACE1
250, 5mcoA, 0.9836, 1.04, 0.997, 383, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE INHIBITOR GRL- 8234 AND EXOSITE PEPTIDE
251, 5hu1A, 0.9836, 0.69, 1.000, 388, 372, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
252, 3l5cA, 0.9836, 0.68, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH723871
253, 5hdzB, 0.9835, 0.70, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
254, 4r93A, 0.9835, 0.70, 1.000, 386, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
255, 4r92A, 0.9835, 0.69, 1.000, 388, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
256, 3udqA, 0.9835, 0.91, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 13
257, 3l5bA, 0.9835, 0.69, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO SCH713601
258, 4wy1A, 0.9834, 0.91, 1.000, 394, 374, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 24B
259, 4jooA, 0.9834, 1.01, 1.000, 402, 375, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
260, 4i0eA, 0.9833, 1.01, 0.997, 393, 375, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
261, 4h1eB, 0.9833, 0.70, 1.000, 387, 372, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
262, 3u6aC, 0.9833, 0.99, 1.000, 384, 375, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
263, 3i25C, 0.9832, 0.59, 0.995, 373, 371, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
264, 5hd0B, 0.9831, 0.71, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
265, 4pzwA, 0.9831, 1.01, 1.000, 397, 375, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
266, 1ym4B, 0.9831, 1.04, 1.000, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
267, 4pzxA, 0.9830, 1.02, 1.000, 400, 375, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
268, 3uqrC, 0.9830, 0.74, 1.000, 377, 372, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
269, 5htzA, 0.9829, 0.72, 1.000, 388, 372, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
270, 4frsA, 0.9829, 0.72, 1.000, 386, 372, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
271, 3udnA, 0.9829, 0.92, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 9
272, 4r8yA, 0.9828, 0.73, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
273, 4h3iA, 0.9828, 0.71, 1.000, 387, 372, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
274, 3n4lC, 0.9828, 0.83, 0.995, 375, 373, BACE-1 IN COMPLEX WITH ELN380842
275, 3duyC, 0.9828, 0.63, 1.000, 374, 371, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
276, 4jpeA, 0.9827, 1.03, 1.000, 402, 375, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
277, 4i0gA, 0.9827, 1.03, 0.997, 393, 375, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
278, 4fm7A, 0.9827, 0.94, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14G
279, 5he4A, 0.9826, 0.73, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
280, 2q11B, 0.9826, 1.04, 0.992, 388, 375, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
281, 3iviB, 0.9824, 0.48, 1.000, 378, 370, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
282, 5hdxA, 0.9823, 0.75, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
283, 4h1eA, 0.9823, 0.74, 1.000, 386, 372, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
284, 5he5A, 0.9822, 0.75, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
285, 5hdzA, 0.9822, 0.75, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
286, 4jpcA, 0.9822, 1.04, 1.000, 402, 375, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
287, 4dpfA, 0.9822, 1.00, 1.000, 375, 374, BACE-1 IN COMPLEX WITH A HEA-MACROCYCLIC TYPE INHIBITOR
288, 5mxdA, 0.9821, 1.01, 1.000, 390, 375, BACE-1 IN COMPLEX WITH LIGAND 32397778
289, 4fm8A, 0.9821, 0.95, 1.000, 394, 374, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12A
290, 2qzkA, 0.9820, 1.09, 0.995, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21
291, 5v0nC, 0.9818, 0.67, 1.000, 377, 371, BACE1 IN COMPLEX WITH INHIBITOR 5G
292, 4i0hA, 0.9818, 0.53, 1.000, 374, 370, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
293, 4dv9A, 0.9818, 1.19, 0.995, 379, 375, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
294, 2zjmA, 0.9817, 1.09, 0.995, 377, 375, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE
295, 4j0zA, 0.9816, 1.07, 0.997, 381, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S5R)-2-AMINO-5-FLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
296, 4i11A, 0.9815, 1.07, 0.997, 397, 375, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES.
297, 3vg1A, 0.9815, 1.14, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A SOAKING EXPERIMENT
298, 2is0A, 0.9814, 1.10, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
299, 2irzA, 0.9814, 1.11, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
300, 4i0zA, 0.9813, 1.00, 0.997, 390, 374, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
301, 3k5fA, 0.9813, 0.71, 0.997, 373, 371, HUMAN BACE-1 COMPLEX WITH AYH011
302, 5hduA, 0.9812, 0.80, 1.000, 387, 372, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
303, 4j17A, 0.9812, 1.07, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-DIFLUOROMETHYL-56-DIHYDRO-4H-[1 3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
304, 2q11C, 0.9812, 1.08, 0.992, 388, 375, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
305, 2b8lA, 0.9812, 1.11, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
306, 5hd0A, 0.9811, 0.78, 1.000, 387, 372, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
307, 4jp9A, 0.9811, 1.09, 1.000, 402, 375, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
308, 3l5dA, 0.9811, 0.67, 1.000, 386, 371, STRUCTURE OF BACE BOUND TO SCH723873
309, 2q11A, 0.9811, 1.09, 0.989, 388, 375, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
310, 4j0vA, 0.9810, 1.09, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
311, 4j0yA, 0.9809, 1.09, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5S)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
312, 4i10A, 0.9809, 1.02, 0.997, 390, 374, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
313, 4dvfB, 0.9809, 0.59, 0.995, 373, 370, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
314, 4j1eA, 0.9808, 1.09, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-FLUOROMETHYL-6-TRIFLUOROMETHYL- 56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
315, 4i0dA, 0.9808, 0.91, 1.000, 387, 373, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
316, 3uqrB, 0.9808, 0.84, 1.000, 374, 372, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
317, 6fgyA, 0.9807, 1.04, 1.000, 379, 374, CRYSTAL STRUCTURE OF HUMAN BACE-1 IN COMPLEX WITH AMINO-1;4-OXAZINE COMPOUND 4 
318, 3ixkB, 0.9806, 0.73, 1.000, 373, 371, POTENT BETA-SECRETASE 1 INHIBITOR
319, 3ixjB, 0.9806, 0.73, 1.000, 373, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
320, 3i25B, 0.9805, 0.74, 1.000, 373, 371, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
321, 4rrsA, 0.9804, 1.02, 0.997, 393, 374, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
322, 3ckpC, 0.9804, 0.91, 0.995, 377, 373, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
323, 2fdpA, 0.9804, 0.73, 1.000, 373, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
324, 5f01A, 0.9803, 1.11, 0.997, 384, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR2SR)-2-((R)-2-AMINO- 55-DIFLUORO-4-METHYL-56-DIHYDRO-4H-13-OXAZIN-4-YL)-N-(3- CHLOROQUINOLIN-8-YL)CYCLOPROPANECARBOXAMIDE
325, 4n00A, 0.9802, 1.03, 0.997, 393, 374, DISCOVERY OF 7-THP CHROMANS: BACE1 INHIBITORS THAT REDUCE A-BETA IN THE CNS
326, 4ke0A, 0.9802, 0.45, 1.000, 375, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
327, 3iviC, 0.9801, 0.46, 1.000, 373, 369, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
328, 3ckrC, 0.9801, 0.92, 0.997, 377, 373, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
329, 2p8hA, 0.9801, 1.16, 0.995, 379, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
330, 4exgA, 0.9799, 0.99, 1.000, 377, 373, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
331, 4b00A, 0.9799, 1.08, 1.000, 375, 374, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND (R)-41)
332, 3duyB, 0.9799, 0.51, 0.997, 370, 369, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
333, 2hizA, 0.9799, 0.50, 1.000, 371, 369, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
334, 4rrnA, 0.9798, 1.05, 0.997, 393, 374, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
335, 3zmgA, 0.9798, 1.12, 0.997, 385, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
336, 2wjoA, 0.9798, 1.01, 1.000, 380, 374, HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H- QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE
337, 2va7A, 0.9798, 1.03, 1.000, 374, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27
338, 2p83A, 0.9798, 0.51, 1.000, 371, 369, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
339, 5dqcA, 0.9797, 0.50, 1.000, 372, 369, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
340, 4rroA, 0.9797, 1.05, 0.997, 393, 374, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
341, 4j0tA, 0.9797, 1.12, 0.997, 381, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-ETHOXY-PYRIDINE-2- CARBOXYLIC ACID [3-((R)-2-AMINO-55-DIFLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
342, 5t1uA, 0.9796, 1.12, 1.000, 380, 375, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
343, 4b77A, 0.9796, 1.08, 1.000, 376, 374, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
344, 4ke0B, 0.9795, 0.76, 1.000, 374, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
345, 4ewoA, 0.9795, 1.00, 1.000, 377, 373, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
346, 5dqcC, 0.9794, 0.79, 0.997, 373, 371, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
347, 4i0jA, 0.9794, 0.65, 0.997, 388, 370, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
348, 4r5nA, 0.9793, 1.07, 0.997, 393, 374, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
349, 4dpiA, 0.9793, 1.03, 0.997, 373, 373, BACE-1 IN COMPLEX WITH HEA-MACROCYCLIC INHIBITOR MV078512
350, 4k8sB, 0.9792, 0.50, 1.000, 371, 369, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
351, 4k8sA, 0.9792, 0.51, 1.000, 371, 369, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
352, 3duyA, 0.9792, 0.35, 1.000, 370, 368, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
353, 3ckpB, 0.9792, 1.07, 0.997, 376, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
354, 5ezzA, 0.9791, 1.20, 0.997, 379, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-CHLORO-3- PYRIDYL)PHENYL]-4-[4-(DIFLUOROMETHOXY)-3-METHYL-PHENYL]-5H-OXAZOL-2- AMINE
355, 4di2B, 0.9791, 0.87, 1.000, 375, 372, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
356, 5ygxA, 0.9790, 1.14, 1.000, 381, 375, STRUCTURE OF BACE1 IN COMPLEX WITH N-(3-((4R;5R;6S)-2-AMINO-6-(1;1- DIFLUOROETHYL)-5-FLUORO-4-METHYL-5;6-DIHYDRO-4H-1;3-OXAZIN-4-YL)-4- FLUOROPHENYL)-5-(FLUOROMETHOXY)PYRAZINE-2-CARBOXAMIDE 
357, 4i0iA, 0.9790, 0.54, 1.000, 372, 369, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
358, 4b72A, 0.9790, 1.11, 1.000, 376, 374, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
359, 3nshA, 0.9790, 0.54, 1.000, 372, 369, BACE-1 IN COMPLEX WITH ELN475957
360, 4di2A, 0.9788, 0.55, 1.000, 375, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
361, 5ygyA, 0.9787, 1.15, 0.995, 381, 375, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH (S)-N-(3-(2-AMINO-6- (FLUOROMETHYL)-4 -METHYL-4H-1;3-OXAZIN-4-YL)-4-FLUOROPHENYL)-5- CYANOPICOLINAMIDE 
362, 4azyA, 0.9787, 1.11, 0.997, 375, 374, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND 10)
363, 3iviA, 0.9787, 0.68, 1.000, 380, 370, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
364, 5i3wA, 0.9785, 1.08, 0.997, 377, 374, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE INHIBITOR 2
365, 4b1eA, 0.9785, 1.13, 1.000, 375, 374, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
366, 5he7A, 0.9784, 0.69, 1.000, 385, 370, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
367, 3ckrB, 0.9784, 1.08, 1.000, 377, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
368, 2va6A, 0.9784, 1.08, 1.000, 376, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 24
369, 3uqpA, 0.9783, 0.87, 0.995, 374, 372, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
370, 2ohsA, 0.9783, 1.07, 1.000, 374, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B
371, 3tpjA, 0.9782, 0.87, 0.995, 377, 372, APO STRUCTURE OF BACE1
372, 4ke0C, 0.9781, 0.56, 1.000, 372, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
373, 4k9hB, 0.9781, 0.42, 1.000, 369, 368, BACE-1 INHIBITOR COMPLEX
374, 6c2iA, 0.9779, 1.08, 1.000, 379, 374, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH : N-(3-((1R5S 6R)-3-AMINO-5-METHYL-2-OXA-4-AZABICYCLO[4.1.0]HEPT-3-EN-5-YL)-4- FLUOROPHENYL)-5-METHOXYPYRAZINE-2-CARBOXAMIDE
375, 4j1fA, 0.9779, 0.90, 0.989, 376, 372, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
376, 3ckpA, 0.9776, 0.81, 1.000, 379, 371, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
377, 2wf1A, 0.9775, 0.99, 0.989, 374, 372, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
378, 4i0iB, 0.9774, 0.46, 1.000, 376, 368, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
379, 3nshB, 0.9774, 0.46, 1.000, 376, 368, BACE-1 IN COMPLEX WITH ELN475957
380, 2wf2A, 0.9774, 1.00, 0.989, 374, 372, HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3478-TETRAHYDRO-1H6H-(125) THIADIAZEPINO(543-DE)QUINOXALINE-10-CARBOXAMIDE 22- DIOXIDE
381, 3ixkC, 0.9773, 0.64, 1.000, 371, 369, POTENT BETA-SECRETASE 1 INHIBITOR
382, 3ivhA, 0.9773, 0.62, 1.000, 379, 369, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
383, 2ohuA, 0.9773, 1.14, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B
384, 2ohkA, 0.9772, 1.10, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1- AMINO-ISOQUINOLINE
385, 4dvfA, 0.9771, 0.73, 0.995, 374, 370, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
386, 4b1dA, 0.9771, 1.17, 1.000, 376, 374, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
387, 3ixjC, 0.9771, 0.65, 1.000, 371, 369, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
388, 3ckrA, 0.9771, 0.83, 1.000, 379, 371, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
389, 4b1cA, 0.9770, 0.98, 0.997, 375, 372, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
390, 2vnnA, 0.9770, 1.00, 0.989, 374, 372, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
391, 2wf3A, 0.9769, 1.01, 0.989, 374, 372, HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-( PHENYLMETHYL)PROPYL)-1-METHYL-1345-TETRAHYDRO-21- BENZOTHIAZEPINE-8-CARBOXAMIDE 22-DIOXIDE
392, 2vieA, 0.9769, 1.02, 0.989, 373, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-1-BENZYL-2-HYDROXY- 3-((115-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2- OXOPYRROLIDIN-1-YL)BENZAMIDE
393, 1w51A, 0.9769, 0.83, 0.997, 374, 371, BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON- PEPTIDIC INHIBITOR
394, 4fcoA, 0.9767, 0.97, 0.995, 374, 372, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
395, 2hizB, 0.9767, 0.53, 1.000, 372, 368, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
396, 4k9hA, 0.9766, 0.51, 1.000, 370, 368, BACE-1 INHIBITOR COMPLEX
397, 2vijA, 0.9766, 1.01, 0.989, 373, 372, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1234-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE
398, 2va5A, 0.9766, 1.14, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C
399, 2ohqA, 0.9765, 1.15, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4
400, 4fgxA, 0.9764, 0.84, 0.995, 374, 371, CRYSTAL STRUCTURE OF BACE1 WITH NOVEL INHIBITOR
401, 2vnmA, 0.9764, 1.03, 0.989, 374, 372, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE
402, 4di2C, 0.9763, 0.54, 1.000, 371, 368, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
403, 2p83B, 0.9763, 0.55, 1.000, 372, 368, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
404, 3mskA, 0.9762, 1.14, 1.000, 377, 374, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
405, 2viyA, 0.9762, 1.08, 0.987, 372, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE
406, 4ivsA, 0.9761, 0.86, 0.995, 373, 371, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
407, 3tppA, 0.9761, 0.98, 0.995, 375, 372, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
408, 2xfiA, 0.9761, 1.07, 0.987, 372, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE
409, 2ohlA, 0.9761, 1.15, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2- AMINOQUINOLINE
410, 1w50A, 0.9761, 1.16, 1.000, 377, 374, APO STRUCTURE OF BACE (BETA SECRETASE)
411, 4j0pA, 0.9759, 0.97, 0.995, 376, 372, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-METHYL-56-DIHYDRO-4H-[13]OXAZIN- 4-YL)-4-FLUORO-PHENYL]-AMIDE
412, 2ohnA, 0.9759, 1.17, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4- (4-FLUOROBENZYL)PIPERIDINE
413, 5v0nA, 0.9757, 0.40, 1.000, 371, 367, BACE1 IN COMPLEX WITH INHIBITOR 5G
414, 2ohmA, 0.9757, 1.16, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-23-DIAMINE
415, 3dm6A, 0.9756, 0.57, 0.997, 369, 368, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
416, 2hizC, 0.9756, 0.72, 1.000, 373, 369, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
417, 5hdvA, 0.9755, 0.70, 1.000, 384, 369, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
418, 4ivtA, 0.9755, 0.87, 0.995, 375, 371, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
419, 2zjjA, 0.9755, 0.68, 0.992, 370, 369, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)- AMIDE
420, 4i0hB, 0.9754, 0.60, 1.000, 375, 368, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
421, 2xfkA, 0.9754, 0.97, 0.989, 371, 371, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-((METHYLSULFONYL)( PHENYL)AMINO)BENZAMIDE
422, 2wezA, 0.9754, 1.09, 0.987, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6-CARBOXAMIDE
423, 2wf4A, 0.9753, 1.09, 0.987, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO- 1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)- 1346-TETRAHYDRO(12)THIAZEPINO(543-CD)INDOLE-8- CARBOXAMIDE 22-DIOXIDE
424, 2p83C, 0.9752, 0.74, 1.000, 373, 369, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
425, 2wf0A, 0.9751, 1.10, 0.987, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE
426, 4b70A, 0.9750, 1.07, 1.000, 372, 372, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
427, 2ohrA, 0.9750, 1.16, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A
428, 4k8sC, 0.9749, 0.73, 1.000, 371, 369, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
429, 3uquA, 0.9749, 0.94, 0.995, 374, 371, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
430, 3s2oA, 0.9749, 1.18, 1.000, 377, 374, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
431, 3uqxA, 0.9748, 0.95, 0.995, 375, 371, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
432, 3tplC, 0.9748, 0.82, 0.992, 370, 370, APO STRUCTURE OF BACE1
433, 2xfjA, 0.9748, 1.11, 0.987, 373, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
434, 4acuA, 0.9747, 0.97, 0.997, 372, 371, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14
435, 2iqgA, 0.9745, 0.63, 1.000, 375, 368, CRYSTAL STRUCTURE OF HYDROXYETHYL SECONDARY AMINE-BASED PEPTIDOMIMETIC INHIBITOR OF HUMAN BETA-SECRETASE (BACE)
436, 2hm1A, 0.9745, 0.63, 1.000, 375, 368, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR (2)
437, 3dm6B, 0.9744, 0.64, 1.000, 368, 368, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
438, 2of0A, 0.9744, 1.20, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5
439, 4d85A, 0.9743, 0.82, 1.000, 374, 370, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BVI151
440, 2vizA, 0.9742, 0.92, 0.992, 370, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE
441, 2qzlA, 0.9741, 0.96, 0.995, 375, 371, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH IXS
442, 2ohtA, 0.9741, 1.23, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7
443, 5v0nB, 0.9740, 0.50, 1.000, 373, 367, BACE1 IN COMPLEX WITH INHIBITOR 5G
444, 3u6aA, 0.9740, 0.94, 1.000, 374, 371, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
445, 2fdpB, 0.9738, 0.52, 1.000, 369, 367, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
446, 3hvgB, 0.9737, 0.77, 1.000, 370, 369, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
447, 2vj9A, 0.9737, 0.92, 0.992, 374, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(CYCLOHEXYLAMINO)- 2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO- 1-PYRROLIDINYL)BENZAMIDE
448, 2ohpA, 0.9736, 1.24, 1.000, 377, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3
449, 2vj6A, 0.9734, 0.94, 0.992, 370, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
450, 5ezxA, 0.9733, 0.88, 0.992, 374, 370, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R2R)-2-[(R)-2-AMINO-4- (4-DIFLUOROMETHOXY-PHENYL)-45-DIHYDRO-OXAZOL-4-YL]-CYCLOPROPYL}-(5- CHLORO-PYRIDIN-3-YL)-METHANONE
451, 4k9hC, 0.9732, 0.70, 1.000, 370, 368, BACE-1 INHIBITOR COMPLEX
452, 2vj7A, 0.9732, 0.94, 0.992, 370, 370, HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
453, 1tqfA, 0.9730, 0.88, 0.995, 371, 370, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
454, 2b8vA, 0.9729, 0.90, 0.995, 373, 370, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L- L000430469
455, 6ej2A, 0.9727, 1.07, 0.995, 377, 372, BACE1 COMPOUND 28 
456, 4acxA, 0.9726, 0.94, 0.997, 370, 370, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23
457, 2ph6A, 0.9725, 0.92, 0.995, 371, 370, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
458, 4i0iC, 0.9724, 0.73, 1.000, 376, 368, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
459, 3uflA, 0.9724, 0.90, 1.000, 373, 370, DISCOVERY OF PYRROLIDINE-BASED B-SECRETASE INHIBITORS: LEAD ADVANCEMENT THROUGH CONFORMATIONAL DESIGN FOR MAINTENANCE OF LIGAND BINDING EFFICIENCY
460, 3r1gB, 0.9724, 1.17, 0.995, 381, 373, STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE- BINDING ANTIBODY
461, 3nshC, 0.9724, 0.73, 1.000, 376, 368, BACE-1 IN COMPLEX WITH ELN475957
462, 3exoA, 0.9724, 0.88, 0.995, 373, 370, CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR
463, 5tolA, 0.9723, 1.10, 0.997, 374, 372, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 COMPLEXED WITH N- (3-((4AS7AS)-2-AMINO-44A56-TETRAHYDRO-7AH-FURO[23-D][1 3]THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-BROMO-2-PYRIDINECARBOXAMIDE
464, 3msjC, 0.9723, 1.01, 1.000, 375, 371, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
465, 2q15A, 0.9721, 1.10, 0.992, 385, 372, STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A
466, 3msjA, 0.9719, 0.93, 1.000, 373, 370, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
467, 5dqcB, 0.9714, 0.66, 0.997, 369, 367, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
468, 4b78A, 0.9710, 1.13, 1.000, 372, 371, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
469, 3hw1A, 0.9707, 0.88, 1.000, 370, 369, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
470, 3uqwA, 0.9706, 1.06, 0.995, 375, 371, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
471, 5mxdB, 0.9705, 0.90, 1.000, 370, 369, BACE-1 IN COMPLEX WITH LIGAND 32397778
472, 3dm6C, 0.9704, 0.57, 1.000, 367, 366, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
473, 5clmA, 0.9703, 1.05, 1.000, 376, 371, 14-OXAZINE BACE1 INHIBITORS
474, 3hvgC, 0.9703, 0.96, 1.000, 373, 370, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
475, 2zjkA, 0.9697, 0.82, 0.997, 371, 368, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
476, 4b05A, 0.9695, 0.96, 0.995, 371, 369, PRECLINICAL CHARACTERIZATION OF AZD3839 A NOVEL CLINICAL CANDIDATE BACE1 INHIBITOR FOR THE TREATMENT OF ALZHEIMER DISEASE
477, 3h0bC, 0.9693, 1.05, 1.000, 373, 370, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
478, 2zjkC, 0.9693, 0.83, 0.997, 371, 368, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
479, 4l7jA, 0.9689, 0.74, 1.000, 374, 367, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
480, 4i0hC, 0.9686, 0.78, 1.000, 374, 367, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
481, 3h0bB, 0.9686, 1.07, 1.000, 373, 370, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
482, 4zpfA, 0.9684, 0.85, 0.995, 371, 368, BACE1 IN COMPLEX WITH 8-(3-((1-AMINOPROPAN-2-YL)OXY)BENZYL)-4- (CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-138-TRIAZASPIRO[4.5]DEC-3-EN- 2-ONE
483, 3hw1C, 0.9684, 1.04, 1.000, 375, 370, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
484, 4bfdA, 0.9682, 0.97, 0.995, 372, 369, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
485, 4l7hA, 0.9681, 0.78, 1.000, 374, 367, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
486, 4wtuA, 0.9678, 0.86, 1.000, 371, 368, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3-AZA-4- FLUORO-XANTHENE INHIBITOR 22
487, 3mslA, 0.9678, 1.34, 1.000, 377, 374, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
488, 3hw1B, 0.9676, 0.80, 1.000, 371, 367, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
489, 4zpeA, 0.9675, 0.89, 0.992, 369, 368, BACE1 IN COMPLEX WITH 4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-8-(3- ISOPROPOXYBENZYL)-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
490, 4b0qA, 0.9674, 1.10, 0.995, 369, 369, LEAD GENERATION OF BACE1 INHIBITORS BY COUPLING NON-AMIDINE NEW WARHEADS TO A KNOWN BINDING SCAFFOLD
491, 3h0bA, 0.9673, 1.09, 1.000, 372, 370, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
492, 4xxsA, 0.9671, 0.91, 1.000, 376, 368, CRYSTAL STRUCTURE OF BACE1 WITH A PYRAZOLE-SUBSTITUTED TETRAHYDROPYRAN THIOAMIDINE
493, 4x2lA, 0.9671, 0.90, 1.000, 371, 368, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 6
494, 2zjkB, 0.9670, 0.82, 0.997, 369, 367, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
495, 4j1iA, 0.9668, 0.94, 0.995, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6R)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
496, 3zovA, 0.9668, 0.93, 0.995, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
497, 4bekA, 0.9666, 0.94, 0.995, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
498, 3rsxA, 0.9665, 1.20, 1.000, 375, 371, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(THIOPHEN-3- YL)QUINOLIN-2-AMINE
499, 4frjA, 0.9662, 0.92, 1.000, 373, 368, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 9L
500, 5uyuA, 0.9661, 0.83, 1.000, 370, 367, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE COMPOUND 12
501, 4friA, 0.9661, 0.94, 1.000, 372, 368, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH BIARYLSPIRO AMINOOXAZOLINE 2 6
502, 5t1wA, 0.9660, 0.93, 1.000, 371, 368, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
503, 5f00A, 0.9660, 0.96, 0.995, 371, 368, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-CHLORO-8- QUINOLYL)AMINO]PHENYL]-5-METHYL-26-DIHYDRO-14-OXAZIN-3-AMINE
504, 4l7gA, 0.9655, 0.87, 0.984, 373, 367, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE1)
505, 3tplA, 0.9655, 0.78, 0.995, 371, 366, APO STRUCTURE OF BACE1
506, 3msjB, 0.9655, 1.04, 1.000, 373, 369, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
507, 4wy6A, 0.9654, 0.96, 1.000, 373, 368, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 36
508, 4zpgA, 0.9652, 0.89, 0.992, 369, 367, BACE1 IN COMPLEX WITH 8-BENZYL-4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)- 7-METHYL-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
509, 3rthA, 0.9647, 1.01, 0.997, 371, 368, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(2-(33- DIMETHYLBUT-1-YNYL)PHENYL)QUINOLIN-2-AMINE
510, 4j1cA, 0.9646, 0.91, 0.997, 371, 367, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-55-DIFLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
511, 3kyrA, 0.9636, 0.49, 1.000, 365, 363, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
512, 4rcfA, 0.9632, 0.86, 0.997, 370, 366, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 4- FLUOROXANTHENE INHIBITOR 49
513, 4frkA, 0.9631, 0.85, 1.000, 369, 366, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 11A
514, 3fktA, 0.9631, 0.86, 0.995, 368, 366, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR
515, 2zjiA, 0.9631, 0.98, 0.995, 370, 367, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(26-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
516, 3tprA, 0.9630, 0.95, 0.997, 368, 367, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
517, 4j1hA, 0.9629, 0.99, 0.995, 370, 367, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6R)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
518, 5i3xA, 0.9625, 1.13, 0.997, 373, 368, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 6
519, 2zhvA, 0.9621, 1.00, 1.000, 370, 367, CRYSTAL STRUCTURE OF BACE1 AT PH 7.0
520, 4rcdA, 0.9618, 0.80, 1.000, 368, 365, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH A 2-AMINOOXAZOLINE 4- AZAXANTHENE INHIBITOR
521, 4dh6A, 0.9617, 0.81, 0.997, 367, 365, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (2R)-N-((2S3R)- 1-(BENZO[D][13]DIOXOL-5-YL)-3-HYDROXY-4-((S)-6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDINE]-4 -YLAMINO) BUTAN-2-YL)-2-METHOXYPROPANAMIDE
522, 6ej3A, 0.9613, 0.82, 1.000, 368, 365, BACE1 COMPOUND 23 
523, 2ewyD, 0.9613, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
524, 2ewyC, 0.9613, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
525, 2ewyB, 0.9613, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
526, 2ewyA, 0.9613, 1.45, 0.551, 374, 372, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
527, 2zhtA, 0.9609, 1.05, 1.000, 370, 367, CRYSTAL STRUCTURE OF BACE1 AT PH 4.5
528, 2ph8A, 0.9607, 0.73, 0.995, 365, 364, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
529, 2zhuA, 0.9606, 1.06, 1.000, 370, 367, CRYSTAL STRUCTURE OF BACE1 AT PH 5.0
530, 3rviA, 0.9604, 1.05, 0.997, 369, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 2-((2-AMINO-6-O- TOLYLQUINOLIN-3-YL)METHYL)-N-(CYCLOHEXYLMETHYL)PENTANAMIDE
531, 5i3vA, 0.9603, 0.98, 0.997, 370, 366, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE COMPOUND 1
532, 3rtmA, 0.9603, 1.05, 0.997, 369, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
533, 2zhsA, 0.9602, 1.06, 1.000, 370, 367, CRYSTAL STRUCTURE OF BACE1 AT PH 4.0
534, 3buhA, 0.9600, 1.00, 0.995, 370, 366, BACE-1 COMPLEXED WITH COMPOUND 4
535, 3braA, 0.9592, 1.03, 0.995, 370, 366, BACE-1 COMPLEXED WITH COMPOUND 1
536, 4j1kA, 0.9585, 0.95, 0.995, 368, 365, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6S)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
537, 4i1cA, 0.9583, 1.03, 1.000, 378, 366, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
538, 3zkqA, 0.9575, 1.55, 0.552, 376, 373, BACE2 XAPERONE COMPLEX
539, 3s7mA, 0.9565, 0.81, 1.000, 371, 363, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
540, 3in3A, 0.9563, 0.83, 1.000, 370, 363, BACE1 WITH COMPOUND 30
541, 3lhgA, 0.9562, 0.83, 1.000, 369, 363, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 4G
542, 5i3yA, 0.9559, 1.04, 1.000, 369, 365, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 9
543, 3s7lA, 0.9557, 0.85, 1.000, 369, 363, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
544, 3igbA, 0.9548, 0.77, 1.000, 369, 362, BACE-1 WITH COMPOUND 3
545, 3kyrB, 0.9547, 0.69, 0.983, 363, 361, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
546, 3oozA, 0.9545, 0.80, 1.000, 368, 362, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 102
547, 3rtnA, 0.9544, 1.07, 0.997, 367, 365, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2-AMINO-6-O- TOLYLQUINOLIN-3-YL)-N-CYCLOHEXYLPROPANAMIDE
548, 2zjnA, 0.9540, 1.06, 0.995, 367, 365, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE
549, 2zdzA, 0.9539, 0.97, 1.000, 370, 363, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10
550, 3in4A, 0.9538, 0.98, 1.000, 370, 363, BACE1 WITH COMPOUND 38
551, 3indA, 0.9532, 0.84, 1.000, 370, 362, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 29
552, 3ineA, 0.9513, 0.84, 0.997, 367, 361, BACE1 WITH THE AMINOHYDANTOIN COMPOUND S-34
553, 4dusA, 0.9502, 1.00, 0.994, 365, 363, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH N-((2S3R)-1-(4- FLUOROPHENYL)-3-HYDROXY-4-((6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDIN]-4 -YL)AMINO) BUTAN-2-YL)ACETAMIDE
554, 4rceA, 0.9500, 0.85, 1.000, 364, 361, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE INHIBITOR 2
555, 3kyrC, 0.9494, 0.55, 1.000, 360, 358, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
556, 4xkxA, 0.9491, 0.89, 0.997, 363, 361, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3- AZAXANTHENE INHIBITOR 28
557, 2qu3A, 0.9490, 0.94, 0.997, 368, 361, BACE1 WITH COMPOUND 2
558, 3rsvA, 0.9465, 0.98, 0.989, 364, 361, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (R)-3-(2-AMINO-6- O-TOLYLQUINOLIN-3-YL)-N-((R)-22-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2- METHYLPROPANAMIDE
559, 3ru1A, 0.9462, 1.00, 0.978, 363, 361, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-(CYCLOHEXYLMETHYL)PROPANAMIDE
560, 3inhA, 0.9458, 0.82, 1.000, 366, 359, BACE1 WITH THE AMINOHYDANTOIN COMPOUND R-58
561, 4i12A, 0.9453, 1.05, 0.994, 374, 361, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
562, 4bfbB, 0.9444, 1.69, 0.554, 374, 368, BACE2 XAPERONE COMPLEX
563, 3zkxA, 0.9431, 1.57, 0.550, 370, 367, TERNARY BACE2 XAPERONE COMPLEX
564, 3infA, 0.9431, 0.82, 0.997, 367, 358, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37
565, 4bfbA, 0.9430, 1.56, 0.555, 373, 366, BACE2 XAPERONE COMPLEX
566, 3vv7A, 0.9423, 0.95, 0.997, 361, 359, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-6-((1S2R)- 2-(3 -METHOXYBIPHENYL-3-YL)CYCLOPROPYL)-3-METHYLPYRIMIDIN-4(3H)-ONE
567, 3l3aA, 0.9422, 0.99, 0.997, 365, 359, BACE-1 WITH THE AMINOPYRIDINE COMPOUND 32
568, 3zlqB, 0.9418, 1.77, 0.554, 370, 368, BACE2 XAPERONE COMPLEX
569, 3wb5A, 0.9417, 0.97, 0.997, 361, 359, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH (6S)-2-AMINO-36- DIMETHYL-6-[(1R2R)-2-PHENYLCYCLOPROPYL]-3456-TETRAHYDROPYRIMIDIN- 4-ONE
570, 5enkA, 0.9413, 0.89, 0.997, 359, 358, COMPOUND 18
571, 3l38A, 0.9408, 0.81, 1.000, 364, 357, BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44
572, 5kr8A, 0.9406, 0.92, 0.997, 359, 358, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-6-(35-DIMETHYL-12-OXAZOL- 4-YL)-4-METHYL-56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 5) BOUND TO BACE1
573, 5ie1A, 0.9401, 1.07, 0.992, 361, 359, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 3-(2-AMINO-6-(O-TOLYL) QUINOLIN-3-YL)-N-(33-DIMETHYLBUTYL)PROPANAMIDE
574, 5enmA, 0.9401, 0.93, 0.997, 359, 358, COMPOUND 10
575, 5kqfA, 0.9398, 0.95, 0.997, 358, 358, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-4-METHYL-6-PYRIMIDIN-5-YL- 56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 12) BOUND TO BACE1
576, 3vv6A, 0.9393, 0.96, 0.997, 360, 358, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S 2R)-2-PHENYLCYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
577, 2qu2A, 0.9387, 0.95, 1.000, 364, 357, BACE1 WITH COMPOUND 1
578, 2ze1A, 0.9374, 0.91, 0.994, 360, 356, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G
579, 3wb4A, 0.9343, 1.02, 0.997, 360, 357, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-36- DIMETHYL-6-(2-PHENYLETHYL)-3456-TETRAHYDROPYRIMIDIN-4-ONE
580, 3zlqA, 0.9342, 1.78, 0.556, 367, 365, BACE2 XAPERONE COMPLEX
581, 3vv8A, 0.9342, 0.96, 0.997, 358, 356, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S2R)-2-(3 -METHYLBIPHENYL-4-YL)CYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
582, 3zkmA, 0.9333, 2.17, 0.545, 375, 369, BACE2 FAB COMPLEX
583, 3bugA, 0.9331, 0.93, 0.994, 357, 355, BACE-1 COMPLEXED WITH COMPOUND 3
584, 3zkgA, 0.9330, 1.47, 0.562, 364, 361, BACE2 MUTANT APO STRUCTURE
585, 3zkmB, 0.9324, 2.19, 0.545, 375, 369, BACE2 FAB COMPLEX
586, 2zjhA, 0.9319, 0.84, 0.997, 356, 354, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE
587, 3zknB, 0.9317, 2.20, 0.545, 375, 369, BACE2 FAB INHIBITOR COMPLEX
588, 3zkiA, 0.9315, 1.56, 0.564, 365, 362, BACE2 MUTANT STRUCTURE WITH LIGAND
589, 3bufA, 0.9307, 1.03, 0.994, 359, 355, BACE-1 COMPLEXED WITH COMPOUND 2
590, 3zknA, 0.9304, 2.23, 0.545, 375, 369, BACE2 FAB INHIBITOR COMPLEX
591, 4ke1A, 0.9279, 0.78, 1.000, 355, 352, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 19
592, 4belA, 0.9248, 1.32, 0.567, 358, 356, BACE2 XAPERONE COMPLEX
593, 3zksA, 0.9229, 1.47, 0.561, 360, 358, BACE2 XAPERONE COMPLEX WITH INHIBITOR
594, 3zkiB, 0.9222, 1.62, 0.565, 361, 359, BACE2 MUTANT STRUCTURE WITH LIGAND
595, 3zl7A, 0.9221, 1.69, 0.547, 363, 360, BACE2 FYNOMER COMPLEX
596, 3zkgB, 0.9200, 1.52, 0.569, 359, 357, BACE2 MUTANT APO STRUCTURE
597, 4belB, 0.9193, 1.38, 0.569, 357, 355, BACE2 XAPERONE COMPLEX
598, 2zjlA, 0.9013, 0.92, 0.994, 344, 343, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-23-DIMETHOXY-BENZYL)-PIPERIDIN- 4-YL]-4-MERCAPTO-BUTYRAMIDE
599, 2rmpA, 0.8083, 2.52, 0.201, 358, 333, RMP-PEPSTATIN A COMPLEX
600, 2asiA, 0.8015, 2.52, 0.202, 356, 331, ASPARTIC PROTEINASE
601, 1mppA, 0.7986, 2.60, 0.217, 357, 332, X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS
602, 5ux4B, 0.7883, 2.37, 0.280, 340, 321, CRYSTAL STRUCTURE OF RAT CATHEPSIN D WITH (5S)-3-(5;6-DIHYDRO-2H- PYRAN-3-YL)-1-FLUORO- 7-(2-FLUOROPYRIDIN-3-YL)SPIRO[CHROMENO[2;3- C]PYRIDINE-5;4 -[1;3]OXAZOL]-2 -AMINE 
603, 5n71A, 0.7816, 2.39, 0.239, 337, 318, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1)
604, 5ux4A, 0.7806, 2.31, 0.290, 337, 317, CRYSTAL STRUCTURE OF RAT CATHEPSIN D WITH (5S)-3-(5;6-DIHYDRO-2H- PYRAN-3-YL)-1-FLUORO- 7-(2-FLUOROPYRIDIN-3-YL)SPIRO[CHROMENO[2;3- C]PYRIDINE-5;4 -[1;3]OXAZOL]-2 -AMINE 
605, 4zl4B, 0.7789, 2.63, 0.196, 395, 322, PLASMEPSIN V FROM PLASMODIUM VIVAX BOUND TO A TRANSITION STATE MIMETIC (WEHI-842)
606, 4zl4A, 0.7789, 2.64, 0.196, 395, 322, PLASMEPSIN V FROM PLASMODIUM VIVAX BOUND TO A TRANSITION STATE MIMETIC (WEHI-842)
607, 5n7qA, 0.7787, 2.50, 0.245, 337, 318, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE INHIBITOR PEPSTATIN A
608, 5n7qB, 0.7782, 2.51, 0.245, 337, 318, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE INHIBITOR PEPSTATIN A
609, 5n7nB, 0.7774, 2.33, 0.244, 361, 316, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
610, 5n7nA, 0.7765, 2.35, 0.244, 361, 316, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
611, 1fq8A, 0.7760, 2.13, 0.250, 329, 312, X-RAY STRUCTURE OF DIFLUOROSTATINE INHIBITOR CP81198 BOUND TO SACCHAROPEPSIN
612, 6c4gA, 0.7755, 2.69, 0.199, 394, 322, PLASMEPSIN V FROM PLASMODIUM VIVAX BOUND TO A TRANSITION STATE MIMETIC (WEHI-601) 
613, 5n7nD, 0.7755, 2.38, 0.241, 360, 316, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
614, 5n7nC, 0.7753, 2.38, 0.244, 361, 316, CRYSTAL STRUCTURE OF CATHEPSIN D ZYMOGEN FROM THE TICK IXODES RICINUS (IRCD1)
615, 2jxrA, 0.7753, 2.15, 0.250, 329, 312, STRUCTURE OF YEAST PROTEINASE A
616, 1fq6A, 0.7752, 2.15, 0.250, 329, 312, X-RAY STRUCTURE OF GLYCOL INHIBITOR PD-133450 BOUND TO SACCHAROPEPSIN
617, 1fq7A, 0.7750, 2.16, 0.250, 329, 312, X-RAY STRUCTURE OF INHIBITOR CP-72647 BOUND TO SACCHAROPEPSIN
618, 1fq4A, 0.7750, 2.15, 0.250, 329, 312, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP- 108420 AND YEAST ASPARTIC PROTEINASE A
619, 4aa8A, 0.7744, 2.33, 0.252, 323, 313, BOVINE CHYMOSIN AT 1.8A RESOLUTION
620, 1qdmA, 0.7744, 2.87, 0.258, 430, 322, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
621, 1fq5A, 0.7744, 2.16, 0.250, 329, 312, X-RAY STRUCTURE OF A CYCLIC STATINE INHIBITOR PD-129541 BOUND TO YEAST PROTEINASE A
622, 5nfgA, 0.7734, 2.35, 0.268, 333, 314, STRUCTURE OF RECOMBINANT CARDOSIN B FROM CYNARA CARDUNCULUS
623, 4aucA, 0.7733, 2.23, 0.256, 323, 312, BOVINE CHYMOSIN IN COMPLEX WITH PEPSTATIN A
624, 1qrpE, 0.7731, 2.16, 0.273, 326, 311, HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL- LEU(P)-(O)PHE-ALA-ALA-OME
625, 1xdhB, 0.7729, 2.37, 0.232, 329, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
626, 5mlgA, 0.7725, 2.32, 0.255, 364, 314, CRYSTAL STRUCTURE OF RAT PRORENIN
627, 1m43B, 0.7724, 2.46, 0.228, 331, 316, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
628, 1psoE, 0.7719, 2.18, 0.273, 326, 311, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
629, 1cziE, 0.7719, 2.47, 0.252, 323, 314, CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972
630, 1w6iC, 0.7716, 2.43, 0.232, 329, 315, PLASMEPSIN II-PEPSTATIN A COMPLEX
631, 1psnA, 0.7714, 2.25, 0.269, 326, 312, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
632, 3d91A, 0.7713, 2.62, 0.244, 334, 316, HUMAN RENIN IN COMPLEX WITH REMIKIREN
633, 2i4qB, 0.7713, 2.65, 0.244, 336, 316, HUMAN RENIN/PF02342674 COMPLEX
634, 1xe5B, 0.7713, 2.42, 0.232, 329, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
635, 1xe6B, 0.7709, 2.41, 0.235, 329, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
636, 1bimB, 0.7709, 2.53, 0.248, 333, 314, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
637, 1bilB, 0.7708, 2.43, 0.249, 333, 313, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
638, 3d91B, 0.7707, 2.71, 0.249, 337, 317, HUMAN RENIN IN COMPLEX WITH REMIKIREN
639, 4q1nB, 0.7703, 2.54, 0.248, 336, 314, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
640, 3ownB, 0.7702, 2.63, 0.251, 334, 315, POTENT MACROCYCLIC RENIN INHIBITORS
641, 1cmsA, 0.7702, 2.39, 0.252, 323, 313, THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION
642, 1me6B, 0.7700, 2.46, 0.232, 329, 315, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
643, 5vpmB, 0.7699, 2.66, 0.247, 335, 316, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
644, 5sy3A, 0.7698, 2.54, 0.248, 333, 314, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
645, 4s1gB, 0.7698, 2.64, 0.248, 338, 315, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
646, 4gjbB, 0.7698, 2.56, 0.248, 335, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
647, 1smeB, 0.7698, 2.47, 0.232, 329, 315, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
648, 4xx4B, 0.7694, 2.55, 0.245, 338, 314, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
649, 1f34A, 0.7694, 2.26, 0.270, 325, 311, CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN
650, 6aprE, 0.7690, 2.38, 0.217, 325, 313, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
651, 4gj9B, 0.7689, 2.56, 0.248, 335, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
652, 3cmsA, 0.7687, 2.39, 0.256, 320, 312, ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN
653, 5pepA, 0.7686, 2.26, 0.270, 326, 311, X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION
654, 5kotB, 0.7685, 2.48, 0.246, 333, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
655, 4gjcB, 0.7685, 2.47, 0.249, 337, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
656, 5tmgB, 0.7684, 2.47, 0.249, 334, 313, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
657, 4gjaB, 0.7684, 2.48, 0.249, 337, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
658, 4gj8B, 0.7684, 2.48, 0.252, 335, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
659, 4gj5B, 0.7684, 2.52, 0.248, 331, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
660, 2il2B, 0.7684, 2.48, 0.252, 338, 313, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
661, 2ikuB, 0.7684, 2.58, 0.252, 337, 314, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
662, 1qdmB, 0.7684, 2.79, 0.276, 430, 319, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
663, 3aprE, 0.7683, 2.39, 0.217, 325, 313, BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION
664, 5aprE, 0.7682, 2.39, 0.217, 325, 313, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
665, 4rz1B, 0.7682, 2.48, 0.246, 336, 313, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
666, 1flhA, 0.7682, 2.26, 0.267, 326, 311, CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION
667, 5vrpA, 0.7681, 2.62, 0.248, 333, 315, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
668, 5vpmA, 0.7681, 2.64, 0.248, 334, 315, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
669, 4rygB, 0.7681, 2.48, 0.249, 337, 313, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
670, 4gjbA, 0.7681, 2.48, 0.252, 335, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
671, 4cmsA, 0.7681, 2.38, 0.260, 320, 312, X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN
672, 3utlA, 0.7681, 2.27, 0.267, 326, 311, HUMAN PEPSIN 3B
673, 3oqkB, 0.7681, 2.48, 0.249, 337, 313, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
674, 1uh7A, 0.7681, 2.40, 0.217, 325, 313, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6
675, 5v8vB, 0.7680, 2.57, 0.252, 337, 314, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
676, 4gj9A, 0.7680, 2.60, 0.252, 333, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
677, 5v8vA, 0.7679, 2.58, 0.252, 337, 314, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
678, 5kosB, 0.7679, 2.48, 0.246, 332, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
679, 1uh9A, 0.7678, 2.40, 0.217, 325, 313, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0
680, 5vrpB, 0.7677, 2.57, 0.252, 333, 314, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
681, 4aprE, 0.7677, 2.40, 0.217, 325, 313, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
682, 3oqfB, 0.7677, 2.48, 0.249, 337, 313, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
683, 1psaB, 0.7677, 2.28, 0.270, 326, 311, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
684, 3q3tA, 0.7676, 2.60, 0.252, 337, 314, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
685, 3ootB, 0.7676, 2.57, 0.248, 337, 314, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
686, 1psaA, 0.7676, 2.34, 0.266, 326, 312, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
687, 4xx3B, 0.7675, 2.48, 0.249, 338, 313, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
688, 2aprA, 0.7675, 2.40, 0.217, 325, 313, STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS
689, 1hrnB, 0.7675, 2.50, 0.246, 333, 313, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
690, 4gjdB, 0.7674, 2.50, 0.249, 337, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
691, 3q5hB, 0.7673, 2.58, 0.252, 338, 314, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
692, 3vyfB, 0.7672, 2.50, 0.249, 335, 313, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
693, 3vydB, 0.7672, 2.50, 0.249, 337, 313, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
694, 1uh8A, 0.7672, 2.41, 0.217, 325, 313, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0
695, 4gjaA, 0.7671, 2.67, 0.244, 337, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
696, 2i4qA, 0.7670, 2.66, 0.244, 336, 315, HUMAN RENIN/PF02342674 COMPLEX
697, 1bilA, 0.7670, 2.64, 0.248, 334, 315, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
698, 4rycB, 0.7669, 2.51, 0.249, 336, 313, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
699, 3q3tB, 0.7669, 2.67, 0.254, 333, 315, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
700, 1yx9A, 0.7669, 2.30, 0.270, 326, 311, EFFECT OF DIMETHYL SULPHOXIDE ON THE CRYSTAL STRUCTURE OF PORCINE PEPSIN
701, 1bbsB, 0.7669, 2.55, 0.248, 331, 314, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
702, 1bbsA, 0.7669, 2.55, 0.248, 331, 314, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
703, 4q1nA, 0.7668, 2.67, 0.244, 336, 315, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
704, 3vyeB, 0.7668, 2.51, 0.249, 335, 313, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
705, 4gjcA, 0.7667, 2.68, 0.244, 337, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
706, 4gj8A, 0.7667, 2.62, 0.252, 334, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
707, 4gj5A, 0.7667, 2.57, 0.248, 332, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
708, 3ownA, 0.7667, 2.66, 0.248, 334, 315, POTENT MACROCYCLIC RENIN INHIBITORS
709, 4gj7B, 0.7666, 2.50, 0.249, 336, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
710, 3vyeA, 0.7666, 2.64, 0.248, 335, 314, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
711, 3q5hA, 0.7666, 2.66, 0.248, 337, 315, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
712, 2ikoA, 0.7666, 2.69, 0.244, 338, 315, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
713, 4rz1A, 0.7665, 2.69, 0.244, 336, 315, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
714, 1ls5B, 0.7665, 2.50, 0.229, 328, 315, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
715, 2il2A, 0.7664, 2.61, 0.245, 338, 314, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
716, 4ya8C, 0.7663, 2.48, 0.232, 329, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
717, 4pyvB, 0.7663, 2.50, 0.249, 334, 313, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
718, 3km4A, 0.7663, 2.53, 0.252, 337, 313, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
719, 1rneA, 0.7663, 2.83, 0.244, 329, 316, THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR
720, 1bimA, 0.7663, 2.65, 0.248, 334, 315, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
721, 3sfcB, 0.7662, 2.54, 0.249, 340, 313, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
722, 3k1wA, 0.7662, 2.72, 0.247, 333, 316, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
723, 2v16O, 0.7662, 2.51, 0.249, 331, 313, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
724, 2ikuA, 0.7662, 2.71, 0.244, 337, 315, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
725, 5tmkB, 0.7661, 2.41, 0.248, 330, 311, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
726, 5sxnB, 0.7661, 2.46, 0.250, 336, 312, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
727, 4pyvA, 0.7661, 2.66, 0.248, 335, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
728, 3q4bB, 0.7661, 2.56, 0.248, 337, 314, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
729, 3q4bA, 0.7661, 2.67, 0.248, 337, 315, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
730, 1hrnA, 0.7661, 2.71, 0.244, 334, 315, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
731, 3k1wB, 0.7660, 2.65, 0.251, 337, 315, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
732, 1qdmC, 0.7660, 2.60, 0.273, 427, 315, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
733, 5nfgB, 0.7659, 2.23, 0.272, 328, 309, STRUCTURE OF RECOMBINANT CARDOSIN B FROM CYNARA CARDUNCULUS
734, 3vydA, 0.7659, 2.65, 0.248, 337, 314, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
735, 3gw5A, 0.7659, 2.62, 0.252, 337, 314, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
736, 2g1sB, 0.7659, 2.31, 0.252, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
737, 4rygA, 0.7658, 2.69, 0.244, 336, 315, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
738, 2v10O, 0.7658, 2.51, 0.249, 331, 313, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
739, 2g1yB, 0.7658, 2.32, 0.248, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
740, 2g1nB, 0.7658, 2.31, 0.248, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
741, 3pepA, 0.7657, 2.31, 0.267, 326, 311, REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN
742, 2g1rB, 0.7657, 2.32, 0.248, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
743, 1am5A, 0.7657, 2.21, 0.274, 324, 310, THE CRYSTAL STRUCTURE AND PROPOSED AMINO ACID SEQUENCE OF A PEPSIN FROM ATLANTIC COD (GADUS MORHUA)
744, 5sz9B, 0.7656, 2.52, 0.250, 332, 312, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
745, 4ya8B, 0.7656, 2.50, 0.222, 329, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
746, 4gjdA, 0.7656, 2.67, 0.248, 335, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
747, 3g70A, 0.7656, 2.62, 0.248, 334, 315, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
748, 2g21B, 0.7656, 2.31, 0.252, 329, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
749, 1fmuA, 0.7655, 2.17, 0.256, 322, 309, STRUCTURE OF NATIVE PROTEINASE A IN P3221 SPACE GROUP.
750, 3km4B, 0.7654, 2.63, 0.252, 333, 314, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
751, 3g70B, 0.7654, 2.57, 0.252, 337, 314, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
752, 1smrG, 0.7654, 2.46, 0.252, 331, 313, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
753, 1smrE, 0.7654, 2.46, 0.252, 331, 313, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
754, 1smrC, 0.7654, 2.46, 0.252, 331, 313, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
755, 1smrA, 0.7654, 2.46, 0.252, 331, 313, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
756, 1fmxA, 0.7654, 2.10, 0.254, 325, 307, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
757, 4xx4A, 0.7653, 2.67, 0.248, 339, 315, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
758, 3vswB, 0.7653, 2.54, 0.249, 340, 313, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
759, 3gw5B, 0.7653, 2.62, 0.252, 332, 314, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
760, 2v12O, 0.7653, 2.53, 0.249, 331, 313, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8
761, 2g1oB, 0.7653, 2.33, 0.248, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
762, 2g24B, 0.7652, 2.32, 0.252, 329, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
763, 2g20B, 0.7652, 2.33, 0.252, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
764, 1dp5A, 0.7652, 2.39, 0.264, 329, 311, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT INHIBITOR
765, 4gj6B, 0.7651, 2.56, 0.248, 333, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
766, 3vsxB, 0.7651, 2.56, 0.249, 340, 313, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
767, 3vsxA, 0.7651, 2.65, 0.248, 340, 314, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
768, 2v11O, 0.7651, 2.62, 0.248, 331, 314, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
769, 1xdhA, 0.7651, 2.53, 0.235, 329, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
770, 1g0vA, 0.7651, 2.35, 0.264, 329, 311, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT MVV
771, 4xx3A, 0.7650, 2.68, 0.248, 339, 315, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
772, 3sfcA, 0.7649, 2.67, 0.248, 340, 314, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
773, 3g72A, 0.7649, 2.68, 0.248, 333, 315, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
774, 2g22B, 0.7648, 2.34, 0.252, 333, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
775, 4s1gA, 0.7647, 2.72, 0.244, 339, 315, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
776, 2g1yA, 0.7647, 2.52, 0.247, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
777, 3vswA, 0.7646, 2.69, 0.248, 340, 315, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
778, 2g1sA, 0.7646, 2.52, 0.247, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
779, 2g1rA, 0.7646, 2.53, 0.247, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
780, 1w6iA, 0.7646, 2.54, 0.235, 329, 315, PLASMEPSIN II-PEPSTATIN A COMPLEX
781, 3vyfA, 0.7645, 2.68, 0.248, 336, 314, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
782, 3vucB, 0.7645, 2.55, 0.252, 338, 313, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
783, 2v0zO, 0.7645, 2.58, 0.246, 336, 313, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
784, 3oqfA, 0.7644, 2.69, 0.248, 337, 315, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
785, 1m43A, 0.7644, 2.61, 0.228, 331, 316, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
786, 2g21A, 0.7643, 2.52, 0.247, 329, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
787, 1me6A, 0.7643, 2.55, 0.232, 329, 315, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
788, 1dpjA, 0.7643, 2.40, 0.264, 329, 311, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR
789, 3oqkA, 0.7642, 2.73, 0.244, 337, 315, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
790, 2v0zC, 0.7642, 2.73, 0.244, 338, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
791, 4gj6A, 0.7641, 2.59, 0.248, 333, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
792, 4ckuB, 0.7641, 2.42, 0.230, 327, 313, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
793, 3g6zB, 0.7641, 2.65, 0.244, 334, 315, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
794, 3g6zA, 0.7641, 2.69, 0.248, 337, 315, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
795, 4gj7A, 0.7640, 2.69, 0.248, 335, 315, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
796, 3ootA, 0.7640, 2.64, 0.252, 337, 314, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
797, 1w6hA, 0.7640, 2.29, 0.232, 325, 311, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
798, 2qzxB, 0.7639, 2.48, 0.234, 342, 312, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
799, 2g24A, 0.7639, 2.54, 0.247, 329, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
800, 1fmxB, 0.7639, 2.14, 0.257, 325, 307, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
801, 3g72B, 0.7638, 2.55, 0.252, 336, 313, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
802, 4rycA, 0.7637, 2.70, 0.248, 336, 315, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
803, 5tmgA, 0.7636, 2.70, 0.248, 334, 315, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
804, 2x0bG, 0.7636, 2.54, 0.247, 329, 312, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
805, 2x0bE, 0.7636, 2.54, 0.247, 329, 312, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
806, 2x0bC, 0.7636, 2.54, 0.247, 329, 312, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
807, 2x0bA, 0.7636, 2.54, 0.247, 329, 312, CRYSTAL STRUCTURE OF HUMAN ANGIOTENSINOGEN COMPLEXED WITH RENIN
808, 2fs4A, 0.7636, 2.54, 0.247, 329, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
809, 2bksA, 0.7636, 2.54, 0.247, 329, 312, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
810, 2g26A, 0.7635, 2.53, 0.247, 329, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
811, 2g22A, 0.7635, 2.55, 0.247, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
812, 2g1oA, 0.7634, 2.52, 0.250, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
813, 5sz9A, 0.7633, 2.70, 0.248, 334, 315, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
814, 2v12C, 0.7633, 2.71, 0.248, 333, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8
815, 2g1nA, 0.7633, 2.51, 0.250, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
816, 1xe6A, 0.7633, 2.56, 0.232, 329, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
817, 4pepA, 0.7632, 2.32, 0.271, 325, 310, THE MOLECULAR AND CRYSTAL STRUCTURES OF MONOCLINIC PORCINE PEPSIN REFINED AT 1.8 ANGSTROMS RESOLUTION
818, 1xe5A, 0.7632, 2.57, 0.232, 329, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
819, 5yicA, 0.7631, 2.50, 0.236, 328, 314, CRYSTAL STRUCTURE OF KNI-10333 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
820, 3vucA, 0.7631, 2.72, 0.248, 340, 315, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
821, 2r9bA, 0.7630, 2.57, 0.235, 329, 315, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
822, 4ckuF, 0.7628, 2.57, 0.222, 329, 315, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
823, 1smeA, 0.7628, 2.60, 0.232, 329, 315, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
824, 5yiaA, 0.7627, 2.51, 0.236, 328, 314, CRYSTAL STRUCTURE OF KNI-10343 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
825, 1lf3A, 0.7627, 2.66, 0.228, 331, 316, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58
826, 5kotA, 0.7626, 2.72, 0.248, 332, 315, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
827, 2v10C, 0.7625, 2.73, 0.248, 333, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
828, 2v11C, 0.7624, 2.65, 0.248, 333, 314, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
829, 5yidA, 0.7623, 2.45, 0.233, 327, 313, CRYSTAL STRUCTURE OF KNI-10395 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
830, 5yieA, 0.7622, 2.46, 0.233, 327, 313, CRYSTAL STRUCTURE OF KNI-10742 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
831, 4ya8D, 0.7622, 2.55, 0.223, 328, 314, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
832, 2v16C, 0.7622, 2.74, 0.248, 333, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
833, 1w6hB, 0.7619, 2.36, 0.232, 325, 311, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
834, 5yibA, 0.7618, 2.52, 0.236, 328, 314, CRYSTAL STRUCTURE OF KNI-10743 BOUND PLASMEPSIN II (PMII) FROM PLASMODIUM FALCIPARUM 
835, 2v13A, 0.7615, 2.76, 0.248, 329, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 7
836, 2r9bB, 0.7613, 2.62, 0.235, 329, 315, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
837, 2qzxA, 0.7613, 2.52, 0.237, 342, 312, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
838, 1ls5A, 0.7613, 2.60, 0.229, 328, 315, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
839, 5t4sA, 0.7612, 2.70, 0.246, 334, 313, NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS
840, 1qs8B, 0.7611, 2.60, 0.229, 328, 314, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
841, 5sxnA, 0.7609, 2.71, 0.246, 336, 313, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
842, 2g20A, 0.7608, 2.59, 0.247, 333, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
843, 2bktB, 0.7608, 2.65, 0.249, 329, 313, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
844, 4ya8A, 0.7607, 2.64, 0.222, 329, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394
845, 5sy3B, 0.7606, 2.67, 0.249, 335, 313, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
846, 5sy2A, 0.7602, 2.71, 0.246, 335, 313, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
847, 5koqA, 0.7602, 2.65, 0.246, 335, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
848, 2g27B, 0.7602, 2.61, 0.250, 328, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
849, 2bktA, 0.7601, 2.61, 0.252, 329, 313, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
850, 3qs1B, 0.7599, 2.65, 0.220, 327, 314, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
851, 3qs1A, 0.7594, 2.67, 0.220, 327, 314, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
852, 5tmkA, 0.7593, 2.72, 0.246, 333, 313, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
853, 5t4sB, 0.7590, 2.56, 0.245, 331, 310, NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS
854, 4ckuD, 0.7587, 2.27, 0.233, 323, 309, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
855, 1wkrA, 0.7587, 2.85, 0.242, 340, 314, CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS
856, 1lf2A, 0.7583, 2.68, 0.232, 329, 315, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370
857, 5i70B, 0.7582, 2.41, 0.229, 321, 310, CRYSTAL STRUCTURE OF PLASMEPSIN IV
858, 2bjuA, 0.7581, 2.65, 0.232, 329, 315, PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR
859, 2renA, 0.7579, 2.31, 0.248, 320, 307, STRUCTURE OF RECOMBINANT HUMAN RENIN A TARGET FOR CARDIOVASCULAR- ACTIVE DRUGS AT 2.5 ANGSTROMS RESOLUTION
860, 2g27A, 0.7579, 2.67, 0.249, 328, 313, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
861, 5koqB, 0.7578, 2.49, 0.243, 333, 309, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
862, 3f9qA, 0.7578, 2.42, 0.235, 325, 311, RE-REFINEMENT OF UNCOMPLEXED PLASMEPSIN II FROM PLASMODIUM FALCIPARUM.
863, 2anlB, 0.7578, 2.53, 0.244, 327, 312, X-RAY CRYSTAL STRUCTURE OF THE ASPARTIC PROTEASE PLASMEPSIN 4 FROM THE MALARIAL PARASITE PLASMODIUM MALARIAE BOUND TO AN ALLOPHENYLNORSTATINE BASED INHIBITOR
864, 2anlA, 0.7578, 2.53, 0.244, 327, 312, X-RAY CRYSTAL STRUCTURE OF THE ASPARTIC PROTEASE PLASMEPSIN 4 FROM THE MALARIAL PARASITE PLASMODIUM MALARIAE BOUND TO AN ALLOPHENYLNORSTATINE BASED INHIBITOR
865, 5kosA, 0.7577, 2.72, 0.249, 331, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
866, 2g26B, 0.7573, 2.47, 0.252, 329, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
867, 1leeA, 0.7572, 2.71, 0.229, 331, 315, CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367
868, 3qrvB, 0.7563, 2.75, 0.225, 329, 315, CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
869, 3emyA, 0.7561, 2.63, 0.226, 328, 314, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN A
870, 2fs4B, 0.7561, 2.50, 0.252, 329, 310, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
871, 2bksB, 0.7561, 2.50, 0.252, 329, 310, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
872, 4y6mA, 0.7559, 2.80, 0.222, 329, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
873, 3qs1C, 0.7556, 2.67, 0.220, 326, 313, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
874, 1qs8A, 0.7556, 2.67, 0.230, 327, 313, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
875, 3qs1D, 0.7555, 2.66, 0.220, 326, 313, CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
876, 1epmE, 0.7555, 2.71, 0.251, 330, 315, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
877, 4er2E, 0.7551, 2.72, 0.251, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
878, 4er1E, 0.7549, 2.72, 0.251, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
879, 1epqE, 0.7549, 2.72, 0.251, 330, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-133 450 (SOT PHE GLY+SCC GCL)
880, 1eppE, 0.7548, 2.72, 0.251, 330, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-130 693 (MAS PHE LYS+MTF STA MBA)
881, 1epnE, 0.7547, 2.72, 0.251, 330, 315, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
882, 3er5E, 0.7546, 2.73, 0.251, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
883, 1entE, 0.7545, 2.72, 0.251, 330, 315, X-RAY ANALYSES OF ASPARTIC PROTEINASES. THE THREE-DIMENSIONAL STRUCTURE AT 2.1 ANGSTROMS RESOLUTION OF ENDOTHIAPEPSIN
884, 4y6mB, 0.7544, 2.75, 0.226, 328, 314, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
885, 1eedP, 0.7544, 2.73, 0.251, 330, 315, X-RAY CRYSTALLOGRAPHIC ANALYSIS OF INHIBITION OF ENDOTHIAPEPSIN BY CYCLOHEXYL RENIN INHIBITORS
886, 2er7E, 0.7543, 2.73, 0.251, 330, 315, X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION
887, 1er8E, 0.7542, 2.73, 0.251, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
888, 5n70A, 0.7541, 2.44, 0.247, 339, 308, CRYSTAL STRUCTURE OF MATURE CATHEPSIN D FROM THE TICK IXODES RICINUS (IRCD1) IN COMPLEX WITH THE N-TERMINAL OCTAPEPTIDE OF THE PROPEPTID
889, 1ppmE, 0.7540, 2.69, 0.228, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
890, 1lf4A, 0.7540, 2.44, 0.235, 325, 310, STRUCTURE OF PLASMEPSIN II
891, 1apuE, 0.7540, 2.69, 0.228, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
892, 3er3E, 0.7539, 2.74, 0.251, 330, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
893, 2webA, 0.7539, 2.69, 0.228, 323, 312, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L- VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3- PHENYLPROPANOATE SODIUM SALT
894, 2er0E, 0.7539, 2.74, 0.251, 330, 315, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES
895, 1bxoA, 0.7539, 2.69, 0.228, 323, 312, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3- METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE
896, 5er2E, 0.7538, 2.73, 0.251, 330, 315, HIGH-RESOLUTION X-RAY DIFFRACTION STUDY OF THE COMPLEX BETWEEN ENDOTHIAPEPSIN AND AN OLIGOPEPTIDE INHIBITOR. THE ANALYSIS OF THE INHIBITOR BINDING AND DESCRIPTION OF THE RIGID BODY SHIFT IN THE ENZYME
897, 2psgA, 0.7538, 2.50, 0.265, 369, 310, REFINED STRUCTURE OF PORCINE PEPSINOGEN AT 1.8 ANGSTROMS RESOLUTION
898, 1apvE, 0.7537, 2.69, 0.228, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
899, 1aptE, 0.7537, 2.69, 0.228, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
900, 1bxqA, 0.7536, 2.69, 0.228, 323, 312, ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR.
901, 4ckuC, 0.7535, 2.39, 0.227, 322, 308, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
902, 4ckuA, 0.7535, 2.43, 0.223, 323, 309, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
903, 1ppkE, 0.7535, 2.69, 0.231, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES
904, 1apwE, 0.7535, 2.70, 0.228, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
905, 2wecA, 0.7533, 2.70, 0.228, 323, 312, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1- NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE SODIUM SALT
906, 4amtA, 0.7532, 2.49, 0.249, 349, 309, CRYSTAL STRUCTURE AT 2.6A OF HUMAN PRORENIN
907, 1eprE, 0.7532, 2.77, 0.251, 329, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-135 040
908, 3psgA, 0.7531, 2.48, 0.272, 365, 309, THE HIGH RESOLUTION CRYSTAL STRUCTURE OF PORCINE PEPSINOGEN
909, 2igyA, 0.7530, 2.78, 0.226, 329, 314, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
910, 2wedA, 0.7529, 2.71, 0.228, 323, 312, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)- ((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2- PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
911, 1pplE, 0.7529, 2.72, 0.231, 323, 312, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
912, 2igyB, 0.7527, 2.85, 0.232, 329, 315, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
913, 2ikoB, 0.7525, 2.58, 0.247, 332, 308, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
914, 4z22B, 0.7524, 2.79, 0.229, 329, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
915, 3urjA, 0.7523, 2.76, 0.248, 328, 315, TYPE IV NATIVE ENDOTHIAPEPSIN
916, 3c9xA, 0.7523, 2.67, 0.232, 328, 314, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE
917, 3urlA, 0.7522, 2.76, 0.248, 328, 315, ENDOTHIAPEPSIN-DB6 COMPLEX.
918, 1e5oE, 0.7521, 2.77, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2
919, 4ckuE, 0.7520, 2.42, 0.227, 322, 308, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
920, 4y6mC, 0.7519, 2.84, 0.223, 329, 314, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
921, 1eplE, 0.7519, 2.77, 0.245, 330, 314, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
922, 1epoE, 0.7518, 2.81, 0.251, 330, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81282 (MOR PHE NLE CHF NME)
923, 2igxA, 0.7517, 2.80, 0.235, 329, 315, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
924, 2er6E, 0.7516, 2.77, 0.245, 330, 314, THE STRUCTURE OF A SYNTHETIC PEPSIN INHIBITOR COMPLEXED WITH ENDOTHIAPEPSIN.
925, 1gvxA, 0.7516, 2.80, 0.251, 328, 315, ENDOTHIAPEPSIN COMPLEXED WITH H256
926, 1gktA, 0.7516, 2.77, 0.248, 328, 315, NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH TRANSITION STATE ANALOGUE INHIBITOR H261
927, 2vs2A, 0.7515, 2.79, 0.248, 328, 315, NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
928, 2jjiA, 0.7515, 2.79, 0.248, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
929, 3uriA, 0.7514, 2.79, 0.251, 328, 315, ENDOTHIAPEPSIN-DB5 COMPLEX.
930, 4apeA, 0.7513, 2.79, 0.245, 330, 314, THE ACTIVE SITE OF ASPARTIC PROTEINASES
931, 3appA, 0.7513, 2.72, 0.228, 323, 312, STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
932, 5er1E, 0.7512, 2.79, 0.245, 330, 314, A RATIONAL APPROACH TO THE DESIGN OF ANTIHYPERTENSIVES. X-RAY STUDIES OF COMPLEXES BETWEEN ASPARTIC PROTEINASES AND AMINOALCOHOL RENIN INHIBITORS
933, 4er4E, 0.7511, 2.81, 0.248, 330, 315, HIGH-RESOLUTION X-RAY ANALYSES OF RENIN INHIBITOR-ASPARTIC PROTEINASE COMPLEXES
934, 2weaA, 0.7511, 2.73, 0.228, 323, 312, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
935, 1oexA, 0.7510, 2.79, 0.251, 328, 315, ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261
936, 3wz8A, 0.7509, 2.77, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (8)
937, 2er9E, 0.7509, 2.79, 0.245, 330, 314, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES.
938, 1gvwA, 0.7509, 2.80, 0.251, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH PD-130328
939, 5hcoA, 0.7508, 2.78, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE
940, 1oewA, 0.7508, 2.79, 0.251, 328, 315, ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN
941, 5p3kA, 0.7507, 2.78, 0.248, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 173
942, 4y48A, 0.7507, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B50
943, 1gvvA, 0.7507, 2.79, 0.251, 328, 315, FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM
944, 1gvtA, 0.7507, 2.79, 0.251, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH CP-80794
945, 1e82E, 0.7507, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD59601
946, 4lbtA, 0.7506, 2.78, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 100MM ACYLHYDRAZONE INHIBITOR
947, 1e81E, 0.7506, 2.79, 0.252, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395
948, 5p3pA, 0.7505, 2.78, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 178
949, 5p1qA, 0.7505, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 109
950, 4z22A, 0.7505, 2.84, 0.225, 329, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
951, 4y3qA, 0.7505, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 109
952, 4y3jA, 0.7505, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B30
953, 5p3rA, 0.7504, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 180
954, 5oz1A, 0.7504, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 12
955, 5p6wA, 0.7503, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 293
956, 5oyrA, 0.7503, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 2
957, 5hctA, 0.7503, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BIACYLHYDRAZONE
958, 4y3mA, 0.7503, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 103
959, 4kupA, 0.7503, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 20MM ACYLHYDRAZONE INHIBITOR
960, 2jjjA, 0.7503, 2.80, 0.251, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
961, 5p5bA, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 236
962, 5p1kA, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 103
963, 5p0cA, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 59
964, 5ozlA, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 32
965, 5oyxA, 0.7502, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 8
966, 5og7A, 0.7502, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE FRAGMENT 
967, 3pbzA, 0.7502, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
968, 5p3yA, 0.7501, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 187
969, 4yd5A, 0.7501, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 236
970, 3wz7A, 0.7501, 2.79, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (6)
971, 5p41A, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 190
972, 5p3nA, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 176
973, 5p3bA, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 164
974, 5p3aA, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 163
975, 5p2nA, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 141
976, 5p0eA, 0.7500, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 61
977, 5oyzA, 0.7500, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 10
978, 5oysA, 0.7500, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 3
979, 4y38A, 0.7500, 2.79, 0.248, 329, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B29
980, 5p82A, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 335
981, 5p7cA, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 309
982, 5p60A, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 261
983, 5p5dA, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 238
984, 5p51A, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 226
985, 5p4bA, 0.7499, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 200
986, 5p4aA, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 199
987, 5p31A, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 154
988, 5p2bA, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 129
989, 5p1cA, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 95
990, 5oz2A, 0.7499, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 13
991, 5oyqA, 0.7499, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 1
992, 4y5bA, 0.7499, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 261
993, 4y44A, 0.7499, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 164
994, 4lhhA, 0.7499, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 2MM ACYLHYDRAZONE INHIBITOR
995, 3pmuA, 0.7499, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
996, 5p7qA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 323
997, 5p6iA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 279
998, 5p66A, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 267
999, 5p5qA, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 251
1000, 5p58A, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 233
1001, 5p4wA, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 221
1002, 5p4lA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 210
1003, 5p4dA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 202
1004, 5p46A, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 195
1005, 5p43A, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 192
1006, 5p40A, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 189
1007, 5p3sA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 181
1008, 5p3lA, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 174
1009, 5p37A, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 160
1010, 5p34A, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 157
1011, 5p33A, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 156
1012, 5p2xA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 150
1013, 5p2jA, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 137
1014, 5p2eA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 132
1015, 5p29A, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 127
1016, 5p26A, 0.7498, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 124
1017, 5p00A, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 47
1018, 5oz4A, 0.7498, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 15
1019, 5oyyA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 9
1020, 5oytA, 0.7498, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 4
1021, 4y5cA, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 267
1022, 4y4jA, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B97
1023, 4y4bA, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 323
1024, 4y3hA, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 189
1025, 4y3aA, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 181
1026, 4y36A, 0.7498, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 4
1027, 5p8hA, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 350
1028, 5p7jA, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 316
1029, 5p77A, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 304
1030, 5p76A, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 303
1031, 5p75A, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 302
1032, 5p6vA, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 292
1033, 5p6nA, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 284
1034, 5p6kA, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 281
1035, 5p62A, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 263
1036, 5p5kA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 245
1037, 5p5jA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 244
1038, 5p5eA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 239
1039, 5p4zA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 224
1040, 5p4uA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 219
1041, 5p4tA, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 218
1042, 5p47A, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 196
1043, 5p42A, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 191
1044, 5p3uA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 183
1045, 5p3tA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 182
1046, 5p3hA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 170
1047, 5p2zA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 152
1048, 5p20A, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 119
1049, 5p1zA, 0.7497, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 118
1050, 5oywA, 0.7497, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 7
1051, 4yd3A, 0.7497, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 224
1052, 1e80E, 0.7497, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD56133
1053, 5p8uA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 363
1054, 5p7uA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 327
1055, 5p7rA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 324
1056, 5p6jA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 280
1057, 5p6cA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 273
1058, 5p64A, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 265
1059, 5p63A, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 264
1060, 5p61A, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 262
1061, 5p55A, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 230
1062, 5p50A, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 225
1063, 5p4pA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 214
1064, 5p4nA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 212
1065, 5p3wA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 185
1066, 5p3mA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 175
1067, 5p3gA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 169
1068, 5p3eA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 167
1069, 5p3dA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 166
1070, 5p2yA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 151
1071, 5p2iA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 136
1072, 5p2fA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 133
1073, 5p1fA, 0.7496, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 98
1074, 5p03A, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 50
1075, 5p02A, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 49
1076, 5ozvA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 42
1077, 5oz9A, 0.7496, 2.79, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 20
1078, 5oz5A, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 16
1079, 5oyvA, 0.7496, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 6
1080, 4y3nA, 0.7496, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 273
1081, 4lp9A, 0.7496, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN COMPLEXED WITH PHE-REDUCED-TYR PEPTIDE.
1082, 3pm4A, 0.7496, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1083, 1gvuA, 0.7496, 2.81, 0.251, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH H189
1084, 5p7oA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 321
1085, 5p71A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 298
1086, 5p6xA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 294
1087, 5p6lA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 282
1088, 5p68A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 269
1089, 5p65A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 266
1090, 5p5yA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 259
1091, 5p5xA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 258
1092, 5p5wA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 257
1093, 5p5rA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 252
1094, 5p5oA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 249
1095, 5p5mA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 247
1096, 5p5lA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 246
1097, 5p4vA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 220
1098, 5p4oA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 213
1099, 5p4fA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 204
1100, 5p49A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 198
1101, 5p48A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 197
1102, 5p45A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 194
1103, 5p3xA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 186
1104, 5p32A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 155
1105, 5p30A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 153
1106, 5p2qA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 143
1107, 5p2gA, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 134
1108, 5p2dA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 131
1109, 5p2aA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 128
1110, 5p28A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 126
1111, 5p25A, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 123
1112, 5p0hA, 0.7495, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 64
1113, 5ozyA, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 45
1114, 5ozqA, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 37
1115, 5oz8A, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 19
1116, 5oz3A, 0.7495, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 14
1117, 4y4eA, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 131
1118, 4y4dA, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B51
1119, 4y43A, 0.7495, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 42
1120, 4y3sA, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 266
1121, 4y3dA, 0.7495, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 321
1122, 3fv3C, 0.7495, 2.51, 0.215, 339, 307, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1123, 5p8fA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 348
1124, 5p80A, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 333
1125, 5p7sA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 325
1126, 5p72A, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 299
1127, 5p6sA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 289
1128, 5p6qA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 287
1129, 5p6gA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 277
1130, 5p6fA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 276
1131, 5p6eA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 275
1132, 5p67A, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 268
1133, 5p5nA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 248
1134, 5p5cA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 237
1135, 5p5aA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 235
1136, 5p59A, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 234
1137, 5p53A, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 228
1138, 5p4cA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 201
1139, 5p3zA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 188
1140, 5p3jA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 172
1141, 5p2oA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 142
1142, 5p1vA, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 114
1143, 5p1rA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 110
1144, 5p1oA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 107
1145, 5p0sA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 75
1146, 5p0qA, 0.7494, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 73
1147, 5p01A, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 48
1148, 5ozuA, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 41
1149, 5oz7A, 0.7494, 2.80, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 18
1150, 5mb3A, 0.7494, 2.81, 0.245, 330, 314, FRAGMENT 333 AT A CONCENTRATION OF 50MM IN COMPLEX WITH ENDOTHIAPEPSIN
1151, 5dr3A, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 333
1152, 5dq2A, 0.7494, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 48
1153, 4ze6A, 0.7494, 2.81, 0.248, 329, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B39
1154, 4y5lA, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN ITS APO FORM
1155, 4y5eA, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 268
1156, 4y4zA, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 73
1157, 4y4uA, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 14
1158, 4y4tA, 0.7494, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 114
1159, 4y3zA, 0.7494, 2.80, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 41
1160, 4y3yA, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B42
1161, 4y39A, 0.7494, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 75
1162, 5p8vA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 364
1163, 5p8oA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 357
1164, 5p8eA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 347
1165, 5p83A, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 336
1166, 5p6pA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 286
1167, 5p6dA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 274
1168, 5p6aA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 271
1169, 5p5pA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 250
1170, 5p5iA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 243
1171, 5p5gA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 241
1172, 5p4mA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 211
1173, 5p4kA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 209
1174, 5p4eA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 203
1175, 5p3qA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 179
1176, 5p3oA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 177
1177, 5p3cA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 165
1178, 5p39A, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 162
1179, 5p36A, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 159
1180, 5p2wA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 149
1181, 5p2vA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 148
1182, 5p2tA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 146
1183, 5p2lA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 139
1184, 5p2hA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 135
1185, 5p23A, 0.7493, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 121
1186, 5p1sA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 111
1187, 5p1pA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 108
1188, 5p1lA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 104
1189, 5p1eA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 97
1190, 5p1aA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 93
1191, 5p19A, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 92
1192, 5p0xA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 80
1193, 5p0nA, 0.7493, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 70
1194, 5lwrA, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A DERIVATIVE OF FRAGMENT 177
1195, 5is4A, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL BROMINATED PRIMARY AMINE FRAGMENT
1196, 5dq5A, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 209
1197, 4yckA, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 211
1198, 4y5kA, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 274
1199, 4y5gA, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 272
1200, 4y4gA, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B53
1201, 4y4aA, 0.7493, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 286
1202, 2h6tA, 0.7493, 2.70, 0.219, 340, 311, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS COMPLEXED WITH PEPSTATIN A
1203, 5p8mA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 355
1204, 5p8bA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 344
1205, 5p7pA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 322
1206, 5p73A, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 300
1207, 5p70A, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 297
1208, 5p6zA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 296
1209, 5p6rA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 288
1210, 5p6mA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 283
1211, 5p6hA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 278
1212, 5p6bA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 272
1213, 5p5zA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 260
1214, 5p5tA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 254
1215, 5p5sA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 253
1216, 5p5hA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 242
1217, 5p54A, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 229
1218, 5p4yA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 223
1219, 5p44A, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 193
1220, 5p2mA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 140
1221, 5p1yA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 117
1222, 5p1xA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 116
1223, 5p1mA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 105
1224, 5p1dA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 96
1225, 5p1bA, 0.7492, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 94
1226, 5p17A, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 90
1227, 5p0uA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 77
1228, 5p0tA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 76
1229, 5p0rA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 74
1230, 5p0oA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 71
1231, 5p0mA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 69
1232, 5oznA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 34
1233, 5ozkA, 0.7492, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 31
1234, 5ozjA, 0.7492, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 30
1235, 5mb7A, 0.7492, 2.81, 0.245, 330, 314, COCKTAIL EXPERIMENT B: FRAGMENTS 224 AND 236 AT 50MM CONCENTRATION
1236, 5dr0A, 0.7492, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 203
1237, 4y37A, 0.7492, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGEMENT 305
1238, 3prsA, 0.7492, 2.84, 0.244, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR
1239, 1ibqA, 0.7492, 2.79, 0.236, 325, 314, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
1240, 5p8tA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 362
1241, 5p8sA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 361
1242, 5p8pA, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 358
1243, 5p8nA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 356
1244, 5p8jA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 352
1245, 5p8gA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 349
1246, 5p8dA, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 346
1247, 5p89A, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 342
1248, 5p86A, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 339
1249, 5p84A, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 337
1250, 5p7yA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 331
1251, 5p7vA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 328
1252, 5p7kA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 317
1253, 5p7gA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 313
1254, 5p78A, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 305
1255, 5p6yA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 295
1256, 5p6oA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 285
1257, 5p69A, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 270
1258, 5p5vA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 256
1259, 5p57A, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 232
1260, 5p56A, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 231
1261, 5p4xA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 222
1262, 5p4sA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 217
1263, 5p4jA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 208
1264, 5p4iA, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 207
1265, 5p3vA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 184
1266, 5p2uA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 147
1267, 5p2rA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 144
1268, 5p2kA, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 138
1269, 5p0zA, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 82
1270, 5p0wA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 79
1271, 5p0gA, 0.7491, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 63
1272, 5p0fA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 62
1273, 5p06A, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 53
1274, 5oz6A, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 17
1275, 5oyuA, 0.7491, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 5
1276, 5dr1A, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 278
1277, 5dq1A, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 34
1278, 5dpzA, 0.7491, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 31
1279, 4y5nA, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 337
1280, 4y5mA, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 328
1281, 4y57A, 0.7491, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 63
1282, 4y3tA, 0.7491, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 207
1283, 4y3eA, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 5
1284, 3pmyA, 0.7491, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1285, 3pi0A, 0.7491, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1286, 3fv3A, 0.7491, 2.52, 0.212, 339, 307, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1287, 5p8rA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 360
1288, 5p8qA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 359
1289, 5p8lA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 354
1290, 5p88A, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 341
1291, 5p81A, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 334
1292, 5p7mA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 319
1293, 5p7lA, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 318
1294, 5p7iA, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 315
1295, 5p7eA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 311
1296, 5p7dA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 310
1297, 5p7aA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 307
1298, 5p79A, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 306
1299, 5p74A, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 301
1300, 5p6tA, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 290
1301, 5p4hA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 206
1302, 5p3fA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 168
1303, 5p38A, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 161
1304, 5p2sA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 145
1305, 5p2cA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 130
1306, 5p24A, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 122
1307, 5p1nA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 106
1308, 5p1jA, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 102
1309, 5p1hA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 100
1310, 5p15A, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 88
1311, 5p0yA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 81
1312, 5p0pA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 72
1313, 5ozdA, 0.7490, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 24
1314, 5ozbA, 0.7490, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 22
1315, 5lwuA, 0.7490, 2.82, 0.245, 330, 314, STRUCTURE RESULTING FROM AN ENDOTHIAPEPSIN CRYSTAL SOAKED WITH A DIMERIC DERIVATIVE OF FRAGMENT 177
1316, 5lwtA, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A METHOXYLATED DERIVATIVE OF FRAGMENT 177
1317, 5dr4A, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 231
1318, 4yd7A, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 255
1319, 4y5aA, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 206
1320, 4y3gA, 0.7490, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 285
1321, 4y35A, 0.7490, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 290
1322, 3t7qA, 0.7490, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1323, 5p8iA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 351
1324, 5p7zA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 332
1325, 5p7xA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 330
1326, 5p7wA, 0.7489, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 329
1327, 5p7tA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 326
1328, 5p7hA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 314
1329, 5p7fA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 312
1330, 5p5uA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 255
1331, 5p52A, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 227
1332, 5p4gA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 205
1333, 5p35A, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 158
1334, 5p1wA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 115
1335, 5p1uA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 113
1336, 5p1tA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 112
1337, 5p1iA, 0.7489, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 101
1338, 5p1gA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 99
1339, 5p18A, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 91
1340, 5p05A, 0.7489, 2.81, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 52
1341, 5ozeA, 0.7489, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 25
1342, 5j25A, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158
1343, 5isjA, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL CHLORINATED PRIMARY AMINE FRAGMENT
1344, 5dr8A, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 330
1345, 5dr7A, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 311
1346, 4yd4A, 0.7489, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 227
1347, 4y51A, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 52
1348, 4y50A, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 81
1349, 4y4cA, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158
1350, 4y3pA, 0.7489, 2.81, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 17
1351, 4y3lA, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 205
1352, 3pgiA, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1353, 3pb5A, 0.7489, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1354, 5p8kA, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 353
1355, 5p8aA, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 343
1356, 5p7bA, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 308
1357, 5p4qA, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 215
1358, 5p27A, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 125
1359, 5p16A, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 89
1360, 5p12A, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 85
1361, 5p11A, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 84
1362, 5p0iA, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 65
1363, 5p08A, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 55
1364, 5ozsA, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 39
1365, 5ozfA, 0.7488, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 26
1366, 5mb6A, 0.7488, 2.82, 0.245, 330, 314, COCKTAIL EXPERIMENT D: FRAGMENTS 308 AND 333 AT 50MM CONCENTRATION
1367, 5lwsA, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 177 AND A DERIVATIVE THEREOF
1368, 4zeaA, 0.7488, 2.82, 0.248, 328, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B91
1369, 4y4wA, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 125
1370, 4y41A, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 112
1371, 4lapA, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP114
1372, 4l6bA, 0.7488, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP128
1373, 5p5fA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 240
1374, 5p14A, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 87
1375, 5p10A, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 83
1376, 5p0vA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 78
1377, 5p0aA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 57
1378, 5ozzA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 46
1379, 5ozxA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 44
1380, 5ozrA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 38
1381, 5oziA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 29
1382, 5ozhA, 0.7487, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 28
1383, 4yd6A, 0.7487, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 240
1384, 3lzyA, 0.7487, 2.82, 0.245, 330, 314, CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON
1385, 3fv3H, 0.7487, 2.53, 0.212, 339, 307, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1386, 3fv3G, 0.7487, 2.53, 0.212, 339, 307, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1387, 5p8cA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 345
1388, 5p87A, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 340
1389, 5p7nA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 320
1390, 5p3iA, 0.7486, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 171
1391, 5p22A, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 120
1392, 5p13A, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 86
1393, 5p0lA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 68
1394, 5p0jA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 66
1395, 5p0dA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 60
1396, 5ozpA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 36
1397, 5ozgA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 27
1398, 5ozcA, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 23
1399, 5oz0A, 0.7486, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 11
1400, 5iskA, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FLUORINATED PRIMARY AMINE FRAGMENT
1401, 5dq4A, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 66
1402, 4y3xA, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 171
1403, 4y3fA, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 78
1404, 3t7xA, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1405, 3pldA, 0.7486, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1406, 1zapA, 0.7486, 2.85, 0.228, 341, 312, SECRETED ASPARTIC PROTEASE FROM C. ALBICANS
1407, 5p85A, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 338
1408, 5p6uA, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 291
1409, 5p0bA, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 58
1410, 5p09A, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 56
1411, 5oztA, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 40
1412, 5ozoA, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 35
1413, 5ozmA, 0.7485, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 33
1414, 5ozaA, 0.7485, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 21
1415, 5mb5A, 0.7485, 2.83, 0.245, 330, 314, COCKTAIL EXPERIMENT C: FRAGMENTS 103 AND 171 IN COMPLEX WITH ENDOTHIAPEPSIN
1416, 4y5pA, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 338
1417, 4y56A, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 58
1418, 4y54A, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 56
1419, 4y53A, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 54
1420, 4y45A, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 291
1421, 4y3wA, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 35
1422, 3pllA, 0.7485, 2.82, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1423, 3fv3E, 0.7485, 2.54, 0.212, 339, 307, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1424, 5mb0A, 0.7484, 2.83, 0.245, 330, 314, COCKTAIL EXPERIMENT A: FRAGMENTS 63 267 AND 291 IN COMPLEX WITH ENDOTHIAPEPSIN
1425, 3pcwA, 0.7484, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1426, 3pbdA, 0.7484, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1427, 2v00A, 0.7484, 2.83, 0.245, 330, 314, X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1
1428, 5p4rA, 0.7483, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 216
1429, 5p07A, 0.7483, 2.82, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 54
1430, 5ozwA, 0.7483, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 43
1431, 4y47A, 0.7483, 2.77, 0.246, 329, 313, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 162
1432, 1od1A, 0.7483, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN PD135040 COMPLEX
1433, 1j71A, 0.7483, 2.62, 0.208, 334, 308, STRUCTURE OF THE EXTRACELLULAR ASPARTIC PROTEINASE FROM CANDIDA TROPICALIS YEAST.
1434, 3tneB, 0.7482, 2.55, 0.215, 339, 307, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
1435, 3t7pA, 0.7482, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A HYDRAZIDE DERIVATIVE
1436, 5p0kA, 0.7481, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 67
1437, 5p04A, 0.7481, 2.83, 0.245, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 51
1438, 4y4xA, 0.7481, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 51
1439, 3psyA, 0.7480, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1440, 3tneA, 0.7479, 2.55, 0.215, 339, 307, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
1441, 3pczA, 0.7479, 2.84, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BENZAMIDINE
1442, 3t6iA, 0.7478, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN AZEPIN DERIVATIVE
1443, 3pwwA, 0.7478, 2.83, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH SAQUINAVIR
1444, 2qzwA, 0.7478, 2.75, 0.215, 341, 311, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
1445, 1izeA, 0.7478, 2.75, 0.225, 323, 311, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN
1446, 3wz6A, 0.7477, 2.84, 0.245, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (5)
1447, 3fv3B, 0.7474, 2.55, 0.215, 339, 307, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1448, 3fv3F, 0.7472, 2.57, 0.212, 339, 307, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1449, 4y58A, 0.7466, 2.82, 0.243, 329, 313, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 260
1450, 4y3rA, 0.7466, 2.81, 0.246, 329, 313, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 306
1451, 3qrvA, 0.7466, 2.63, 0.220, 323, 309, CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM
1452, 5sy2B, 0.7465, 2.53, 0.249, 330, 305, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
1453, 3fv3D, 0.7460, 2.56, 0.216, 338, 306, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1454, 2h6sA, 0.7454, 2.86, 0.218, 340, 312, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS
1455, 4aa9A, 0.7453, 2.24, 0.275, 313, 302, CAMEL CHYMOSIN AT 1.6A RESOLUTION
1456, 4yctA, 0.7452, 2.84, 0.246, 328, 313, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 216
1457, 1eagA, 0.7452, 2.85, 0.230, 339, 309, SECRETED ASPARTIC PROTEINASE (SAP2) FROM CANDIDA ALBICANS COMPLEXED WITH A70450
1458, 3vcmB, 0.7434, 2.56, 0.250, 325, 304, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1459, 3fntA, 0.7429, 2.68, 0.245, 323, 310, CRYSTAL STRUCTURE OF PEPSTATIN A BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1460, 4rldB, 0.7426, 2.57, 0.160, 330, 307, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1461, 3fnuD, 0.7423, 2.77, 0.237, 326, 312, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1462, 3fnuC, 0.7420, 2.78, 0.240, 326, 312, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1463, 1ibqB, 0.7418, 2.80, 0.240, 325, 312, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
1464, 3lizA, 0.7417, 2.73, 0.159, 329, 309, CRYSTAL STRUCTURE OF BLA G 2 COMPLEXED WITH FAB 4C3
1465, 4rldA, 0.7416, 2.58, 0.160, 330, 307, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1466, 2nr6A, 0.7414, 2.69, 0.159, 329, 308, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1467, 1yg9A, 0.7414, 2.65, 0.160, 329, 307, THE STRUCTURE OF MUTANT (N93Q) OF BLA G 2
1468, 1tzsA, 0.7414, 2.38, 0.265, 322, 302, CRYSTAL STRUCTURE OF AN ACTIVATION INTERMEDIATE OF CATHEPSIN E
1469, 2nr6B, 0.7413, 2.69, 0.159, 329, 308, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1470, 5i70A, 0.7410, 2.37, 0.231, 315, 303, CRYSTAL STRUCTURE OF PLASMEPSIN IV
1471, 5jodB, 0.7408, 2.91, 0.235, 375, 315, STRUCTURE OF PROPLASMEPSIN IV FROM PLASMODIUM FALCIPARUM
1472, 4ybfA, 0.7407, 2.69, 0.221, 334, 308, ASPARTIC PROTEINASE SAPP2 SECRETED FROM CANDIDA PARAPSILOSIS AT 1.25 A RESOLUTION
1473, 4rldC, 0.7403, 2.53, 0.160, 330, 306, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1474, 2qzwB, 0.7401, 2.92, 0.219, 341, 311, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
1475, 1avfJ, 0.7401, 2.45, 0.248, 322, 303, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
1476, 4rldD, 0.7394, 2.54, 0.160, 330, 306, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1477, 3q70A, 0.7380, 2.60, 0.237, 334, 304, SECRETED ASPARTIC PROTEASE IN COMPLEX WITH RITONAVIR
1478, 1izdA, 0.7373, 2.93, 0.225, 323, 311, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE
1479, 3fnuA, 0.7369, 2.88, 0.240, 326, 312, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1480, 3fnuB, 0.7368, 2.88, 0.240, 326, 312, CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1481, 3pvkA, 0.7361, 2.48, 0.233, 330, 301, SECRETED ASPARTIC PROTEASE 2 IN COMPLEX WITH BENZAMIDINE
1482, 3fnsB, 0.7359, 2.92, 0.237, 325, 312, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1483, 1avfA, 0.7346, 2.45, 0.239, 320, 301, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
1484, 4ycyA, 0.7341, 2.82, 0.247, 323, 308, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 218
1485, 3vcmA, 0.7340, 2.79, 0.250, 335, 304, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1486, 3fnsA, 0.7328, 2.98, 0.237, 325, 312, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1487, 4y9wA, 0.7320, 2.52, 0.226, 327, 301, ASPARTIC PROTEINASE SAPP2 SECRETED FROM CANDIDA PARAPSILOSIS AT 0.82 A RESOLUTION.
1488, 5bwyA, 0.7275, 3.13, 0.229, 376, 315, STRUCTURE OF PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM SPACE GROUP P43212
1489, 3vlaA, 0.7273, 3.48, 0.149, 412, 322, CRYSTAL STRUCTURE OF EDGP
1490, 1htrB, 0.7265, 2.92, 0.248, 329, 303, CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION
1491, 4pphE, 0.7261, 3.33, 0.174, 391, 316, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1492, 4pphF, 0.7256, 3.35, 0.177, 392, 316, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1493, 3vlbC, 0.7251, 3.46, 0.150, 403, 321, CRYSTAL STRUCTURE OF XEG-EDGP
1494, 4pphB, 0.7250, 3.27, 0.175, 391, 315, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1495, 3aupB, 0.7250, 3.17, 0.143, 372, 314, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1496, 1t6gB, 0.7248, 3.12, 0.148, 368, 311, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1497, 1t6gA, 0.7245, 3.13, 0.148, 368, 311, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1498, 3vlbA, 0.7243, 3.50, 0.149, 404, 322, CRYSTAL STRUCTURE OF XEG-EDGP
1499, 4pphC, 0.7226, 3.33, 0.175, 392, 315, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1500, 4pphD, 0.7223, 3.31, 0.175, 392, 315, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1501, 3qviC, 0.7221, 2.98, 0.230, 327, 305, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1502, 1t6eX, 0.7210, 3.34, 0.140, 362, 314, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR I
1503, 4pphA, 0.7203, 3.38, 0.171, 390, 315, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1504, 3qviB, 0.7203, 2.96, 0.236, 327, 305, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1505, 3qviD, 0.7183, 3.02, 0.236, 327, 305, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1506, 3qvcA, 0.7177, 3.23, 0.226, 368, 314, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) ZYMOGEN FROM PLASMODIUM FALCIPARUM
1507, 5jodA, 0.7174, 3.20, 0.220, 375, 313, STRUCTURE OF PROPLASMEPSIN IV FROM PLASMODIUM FALCIPARUM
1508, 3aupC, 0.7174, 3.38, 0.150, 372, 314, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1509, 3aupA, 0.7167, 3.20, 0.151, 377, 311, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1510, 5mktA, 0.7157, 2.34, 0.258, 329, 291, CRYSTAL STRUCTURE OF MOUSE PRORENIN
1511, 3hd8A, 0.7152, 3.43, 0.147, 370, 312, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1512, 1miqB, 0.7138, 3.22, 0.224, 375, 313, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1513, 1miqA, 0.7130, 3.21, 0.223, 373, 310, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1514, 1pfzB, 0.7129, 3.04, 0.221, 369, 308, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1515, 1pfzA, 0.7129, 3.03, 0.224, 370, 308, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1516, 2b42A, 0.7124, 3.29, 0.143, 364, 308, CRYSTAL STRUCTURE OF THE TRITICUM XYLANSE INHIBITOR-I IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1517, 1pfzD, 0.7120, 3.09, 0.231, 369, 308, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1518, 3hd8C, 0.7108, 3.35, 0.149, 368, 309, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1519, 1pfzC, 0.7073, 3.18, 0.221, 356, 308, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1520, 3qviA, 0.7058, 3.15, 0.239, 323, 301, CRYSTAL STRUCTURE OF KNI-10395 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM
1521, 3aupD, 0.7028, 3.18, 0.149, 360, 303, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1522, 3q6yA, 0.7017, 2.86, 0.251, 305, 295, ENDOTHIAPEPSIN IN COMPLEX WITH A PYRROLIDINE BASED INHIBITOR
1523, 4ehcA, 0.5830, 3.44, 0.132, 275, 257, CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF RV0977 OF MYCOBACTERIUM TUBERCULOSIS
1524, 1b5fA, 0.5664, 2.04, 0.260, 239, 227, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
1525, 4oc6B, 0.5645, 2.37, 0.283, 243, 230, STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-BROMO-N-[(2S3S)-4-{[2-(24- DICHLOROPHENYL)ETHYL][3-(13-DIOXO-13-DIHYDRO-2H-ISOINDOL-2-YL) PROPANOYL]AMINO}-3-HYDROXY-1-(3-PHENOXYPHENYL)BUTAN-2-YL]-45- DIMETHOXYBENZAMIDE
1526, 1lyaB, 0.5642, 2.21, 0.285, 241, 228, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1527, 1lyaD, 0.5635, 2.21, 0.281, 241, 228, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1528, 1lybB, 0.5634, 2.24, 0.281, 241, 228, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1529, 1b5fC, 0.5634, 2.05, 0.265, 238, 226, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
1530, 4od9D, 0.5624, 2.36, 0.275, 241, 229, STRUCTURE OF CATHEPSIN D WITH INHIBITOR N-(34-DIMETHOXYBENZYL)- NALPHA-{N-[(34-DIMETHOXYPHENYL)ACETYL]CARBAMIMIDOYL}-D- PHENYLALANINAMIDE
1531, 1lybD, 0.5621, 2.27, 0.281, 241, 228, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
1532, 4od9B, 0.5611, 2.31, 0.276, 240, 228, STRUCTURE OF CATHEPSIN D WITH INHIBITOR N-(34-DIMETHOXYBENZYL)- NALPHA-{N-[(34-DIMETHOXYPHENYL)ACETYL]CARBAMIMIDOYL}-D- PHENYLALANINAMIDE
1533, 4obzB, 0.5605, 2.32, 0.272, 240, 228, STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-(34-DIMETHOXYPHENYL)-N-[N- (4-METHYLBENZYL)CARBAMIMIDOYL]ACETAMIDE
1534, 1lywD, 0.5582, 2.50, 0.266, 241, 229, CATHEPSIN D AT PH 7.5
1535, 1lywB, 0.5582, 2.54, 0.275, 241, 229, CATHEPSIN D AT PH 7.5
1536, 1lywF, 0.5581, 2.52, 0.266, 241, 229, CATHEPSIN D AT PH 7.5
1537, 1lywH, 0.5576, 2.55, 0.284, 241, 229, CATHEPSIN D AT PH 7.5
1538, 4obzD, 0.5540, 2.25, 0.286, 237, 224, STRUCTURE OF CATHEPSIN D WITH INHIBITOR 2-(34-DIMETHOXYPHENYL)-N-[N- (4-METHYLBENZYL)CARBAMIMIDOYL]ACETAMIDE
